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ABSTRACT:	  In	  order	  to	  provide	  α-­‐substituted	  piperazines	  for	  early-­‐stage	  medicinal	  chemistry	  studies,	  a	  simple,	  general	  
synthetic	  approach	  is	  required.	  Here,	  we	  report	  the	  development	  of	  two	  general	  and	  simple	  procedures	  for	  the	  racemic	  
lithiation/trapping	  of	  N-­‐Boc	  piperazines.	  Optimum	  lithiation	  times	  have	  been	  determined	  using	   in	  situ	   IR	  spectroscopy	  
and	  the	  previous	  complicated	  and	  diverse	  literature	  procedures	  have	  been	  simplified.	  Subsequent	  trapping	  with	  electro-­‐
philes	  delivered	  a	  wide	  range	  of	  α-­‐functionalised	  N-­‐Boc	  piperazines.	  The	  scope	  and	  limitations	  of	  the	  distal	  N-­‐group	  has	  
been	  investigated.	  The	  selective	  α-­‐	  and	  β-­‐	  arylation	  of	  N-­‐Boc	  piperazines	  via	  lithiation/Negishi	  coupling	  is	  reported.	  
Piperazines	  are	  privileged	  groups	  within	  small	  molecule	  
drugs.	   Of	   the	   1175	   drugs	   approved	   by	   the	   FDA	   between	  
1983	  and	  2012,	  51	  drugs	  contain	  the	  motif,	  making	  pipera-­‐
zine	  the	  4th	  most	  common	  ring	  in	  drugs1	  and	  the	  3rd	  most	  
common	  nitrogen	  heterocycle.2	  Nevertheless,	  piperazines	  
substituted	  at	  carbon	  are	  rare	  within	  small	  molecule	  ther-­‐
apeutics,	   with	   Indinavir3	   (an	   antiretroviral)	   and	   Vestipi-­‐
tant	   (a	  NK-­‐1	   antagonist	   currently	   in	   clinical	   trials)	   being	  
notable	  examples	  (Figure	  1).4	  
Figure	   1.	   Structures	  of	  bio-­‐active	  piperazines	   Indi-­‐
navir	  and	  Vestipitant	  
	  
The	   use	   of	   α-­‐substituted	   piperazines	   in	   medicinal	  
chemistry	   is	   somewhat	   limited	  by	  their	  poor	  commercial	  
availability	  and	  the	  lack	  of	  simple	  methods	  for	  their	  syn-­‐
thesis.	  Available	  approaches	  include	  the	  formation	  of	  the	  
piperazine	  ring,	  traditionally	  from	  amino	  acids	  (via	  keto-­‐
piperazines),5	  or	  more	  recently	  via	  Mitsunobu	  chemistry,6	  
Pd-­‐7	   or	   Au-­‐catalysis,8	   photoredox	   catalysis,9	   or	   Bode’s	  
SnAP10	   and	   SLAP11	   reagents.	  The	   direct	   functionalization	  
of	   the	   intact	   piperazine	   ring	   is	   an	   alternative	   strategy,	  
allowing	   late	   stage	   introduction	   of	   the	   α-­‐substituent.	   As	  
an	  example,	  photoredox	  catalysis	  has	  been	  used	  for	  direct	  
α-­‐arylation	   and	   vinylation	   of	   N-­‐aryl	   substituted	   pipera-­‐
zines	   but	   is	   limited	   to	  N-­‐aryl	   substituents.12	   In	   2016,	   we	  
reported	  a	  route	  to	  a	  wide	  range	  of	  α-­‐substituted	  pipera-­‐
zines	   via	   the	   enantioselective	   α-­‐lithiation/trapping	   of	  N-­‐
Boc	  piperazines.13,14	  Although	  this	  previous	  study	   focused	  
on	   the	   arguably	   more	   challenging	   asymmetric	   reaction,	  
there	   remains	   a	   need	   to	   explore	   conditions	   for	   racemic	  
lithiation/trapping	   for	   the	   following	   reasons.	  First,	   early-­‐
stage	  medicinal	  chemistry	  studies	  require	  rapid	  access	  to	  
racemic	   products.	   Second,	   the	   racemic	   and	   asymmetric	  
reactions	   do	   not	   always	   behave	   analogously.	   Third,	   the	  
racemic	   lithiation/trapping	   of	  N-­‐Boc	   piperazines	   is	   rela-­‐
tively	  under	  investigated	  and	  the	  few	  reports15	  have	  signi-­‐
ficant	   variation	   in	   the	   conditions	   used,	   involving	   very	  
different	  reaction	  times	  and	  temperatures	  (Scheme	  1).	  For	  
example,	   van	  Maarseveen’s	   conditions	   involved	  multiple	  
warm/cool	   cycles.15a	   Subsequent	   reports	   by	   Coldham15b	  
and	  ourselves15c	  employed	  either	  lengthy	  reaction	  times	  at	  
–78	   °C	   or	   short	   reaction	   times	   at	   elevated	   temperatures.	  
Additional	  reports,	  focused	  on	  target	  synthesis,	  have	  used	  
further	  modifications	  of	  these	  procedures.15d-­‐i	  	  
Scheme	   1.	  Direct	   Functionalization	  of	  N-­‐Boc	  Pipera-­‐
zines	  via	  Lithiation/Trapping	  
 
Due	  to	  the	  wide	  range	  of	  experimental	  conditions	  that	  
have	  been	   reported	   to	  date	  and	   the	  need	   to	  have	   simple	  
access	   to	   racemic	   products	   for	  medicinal	   chemistry	   stu-­‐
dies,	  we	  set	  out	  to	  develop	  a	  general,	  unified	  and	  experi-­‐
mentally	  simple	  procedure	  for	  the	  direct	  functionalization	  
of	   N-­‐Boc	   piperazines	   via	   racemic	   lithiation/trapping	  
(Scheme	  1).	  Herein,	  we	  report	  our	  results	  and	  present	  two	  
 
complementary,	  general	  procedures	  which	  were	  informed	  
by	  in	  situ	  IR	  spectroscopic	  studies.	  
The	  simplest	  piperazine	  lithiation	  protocol	  involves	  the	  
use	  of	   commercially	   available,	  orthogonally	  protected	  N-­‐
Boc-­‐N’-­‐benzyl	   piperazine	   1	   and	   diamine-­‐free	   lithiation	  
conditions,	   carried	   out	   at	   easily	   manageable	   (on	   a	   re-­‐
search	  scale)	  cryogenic	  conditions	  (–78	  °C).	  Additionally,	  
in	  our	  hands,	  we	  found	  that	  performing	  the	  reactions	  at	  –
78	  °C	  gave	  more	  reproducible	  yields	  than	  when	  using	  our	  
previously	  published	  high-­‐temperature	  (–30	  °C)	  lithiation	  
conditions.15c	  To	  assess	  the	  feasibility	  of	  such	  a	  system,	  we	  
employed	  the	  use	  of	  in	  situ	  IR	  spectroscopy	  to	  identify	  the	  
time	   taken	   for	   lithiation	   (by	   monitoring	   the	   change	   in	  
νC=O).
16	   A	   solution	   of	   1	   in	   THF	   at	   –78	   °C	   showed	   a	   νC=O	  
peak	  at	  1696	  cm-­‐1.	  Upon	  addition	  of	  s-­‐BuLi,	  lithiation	  of	  1	  
proceeded	   to	   give	   lithiated	   intermediate	   2	   (νC=O	   peak	   at	  
1645	  cm-­‐1)	  in	  1	  h	  (Scheme	  2).	  In	  contrast	  to	  our	  previous	  in	  
situ	   IR	   spectroscopic	   studies	   with	   s-­‐BuLi/diamines	   in	  
Et2O,	  the	  pre-­‐lithiation	  species	  was	  not	  detected.
16b	  
Scheme	  2.	  In	  situ	  IR	  Spectroscopic	  Monitoring	  of	  the	  
s-­‐BuLi/THF-­‐mediated	  Lithiation	  of	  N-­‐Boc	  Piperazine	  
1	  	  
	  
Scheme	   3.	   Lithiation/Trapping	   of	   N-­‐Boc-­‐N-­‐benzyl	  
Piperazine	  1	  	  	  
	  
Having	  determined	  the	   time	  required	   for	   the	  diamine-­‐
free	  lithiation	  of	  1,	  the	  full	  lithiation/trapping	  process	  was	  
investigated.	   Treatment	   of	  N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1	  
with	  1.3	  eq.	  of	  s-­‐BuLi	  in	  THF	  at	  –78	  °C	  for	  1	  h	  followed	  by	  
addition	   of	   the	   electrophile	   gave	   α-­‐substituted	   pipera-­‐
zines	  3a-­‐g	  in	  44–90%	  yields	  (Scheme	  3).	  Good	  yields	  (60-­‐
74%)	  were	   obtained	  with	  Me3SiCl,	   Bu3SnCl,	  MeI,	  methyl	  
chloroformate	   and	   paraformaldehyde.	   The	   use	   of	   cyclo-­‐
hexanone	  and	  benzophenone	  gave	  oxazolidinones	  3f	  and	  
3g	   in	   44%	   and	   90%	   respectively,	   after	   cyclisation	   of	   the	  
intermediate	  alkoxide	  on	  to	  the	  Boc	  group.	  The	  low	  yield	  
of	  3f	  is	  probably	  due	  to	  the	  electrophile	  undergoing	  facile	  
enolisation.	  
With	  an	  operationally	  simple	  lithiation/trapping	  proce-­‐
dure	   established,	   we	   chose	   to	   investigate	   the	   substrate	  
scope	   and	   varied	   the	   expectedly	   innocuous	   distal	   N-­‐
substituent.	   Interestingly,	   our	   optimized	   diamine-­‐free	  
lithiation	  protocol	  gave	  varied	  results	  when	  applied	  to	  N-­‐
Boc-­‐N’-­‐methyl	   piperazine	   4.	   Lithiation	   under	   our	   stand-­‐
ard	  conditions	  (s-­‐BuLi,	  THF,	  –78	  °C,	  1	  h)	  proceeded	  in	  the	  
usual	   way,	   as	   shown	   by	   in	   situ	   IR	  monitoring	   (see	   Sup-­‐
porting	   Information)	   However,	   trapping	   with	   Me3SiCl	  
gave	   no	   α-­‐silylated	   piperazine	   6	   (Scheme	   4).	   The	   only	  
product	   observed	   by	   1H	  NMR	   spectroscopy	  was	   the	   ring	  
fragmented	   side-­‐product	   5,	   which	   was	   isolated	   in	   30%	  
yield.	  As	  reported	  in	  our	  study	  into	  the	  asymmetric	  lithia-­‐
tion/trapping	  of	  N-­‐Boc	  piperazines,13	   this	   side-­‐product	   is	  
formed	   by	   attack	   of	   the	   distal	   nitrogen	   on	   the	   electro-­‐
phile,	   followed	   by	   ring	   fragmentation	   and	   N-­‐Si	   bond	  
cleavage	   upon	   work-­‐up.	   Likewise,	   trapping	   with	   methyl	  
chloroformate	   gave	   ring	   fragmented	   side-­‐products	  7	   and	  
8	   in	   34%	   and	   11%	   yields	   respectively.	   The	   latter	   formed	  
from	   a	   subsequent	   Boc-­‐directed	   vinylic	   lithiation	   (and	  
trapping)	  event.	  In	  contrast,	  trapping	  with	  benzophenone	  
gave	   α-­‐substituted	   products	   9	   and	   10	   in	   83%	   and	   12%	  
yields	  with	  no	  evidence	  of	  ring	  fragmented	  side-­‐products.	  
We	   suggest	   that	   ketones	   are	   less	   likely	   to	   interact	   with	  
the	   distal	   nitrogen	   lone	   pair	   than	   Me3SiCl	   and	   methyl	  
chloroformate	  and	  so	  ring	  fragmentation	  did	  not	  occur.	  
Scheme	   4.	   Lithiation/Trapping	   of	   N-­‐Boc-­‐N-­‐methyl	  
Piperazine	  4	  	  	  
	  
Our	  unsuccessful	  trapping	  of	  lithiated	  N-­‐Boc-­‐N’-­‐methyl	  
piperazine	  4	  with	  Me3SiCl	  was	   reminiscent	  of	   van	  Maar-­‐
seveen	   et	   al.’s	   result.	   When	   lithiating	   4	   under	   different	  
conditions	  they	  isolated	  only	  5%	  of	  the	  desired	  α-­‐silylated	  
piperazine	   6	   when	   trapping	   with	   Me3SiCl.
15a	   To	   verify	  
whether	  their	  low	  yield	  was	  in	  fact	  due	  to	  ring	  fragmenta-­‐
tion,	   we	   repeated	   van	   Maarseveen’s	   experiment.	   In	   our	  
 
hands,	  none	  of	  the	  desired	  product	  6	  was	  formed	  and	  the	  
only	  fragmentation	  side-­‐products	  5	  (isolated	  in	  37%	  yield)	  
and	   vinyl	   silane	   11	   (isolated	   in	   32%)	   were	   observed	  
(Scheme	  5).	  	  
Scheme	   5.	   Explanation	   of	   the	   Failure	   of	   the	   Lithia-­‐
tion/Trapping	  of	  4	  with	  Me3SiCl	  	  	  
	  
Thus,	  the	  use	  of	  a	  small	  distal	  N-­‐substituent	  led	  to	  limi-­‐
tations	   with	   some	   electrophiles	   (Me3SiCl	   and	   methyl	  
chloroformate)	   due	   to	   ring	   fragmentation.	   In	   contrast	  
increasing	   the	   size	  of	   the	  group	   led	   to	   a	  pronounced	   re-­‐
duction	   in	   the	   rate	   of	   lithiation.	   Initial	   in	   situ	   IR	   studies	  
with	   the	   previously	   reported14,15b	   N-­‐Boc-­‐N’-­‐tert-­‐butyl	   pi-­‐
perazine	  12	  showed	  that	  diamine-­‐free	  lithiation	  was	  much	  
slower	   than	   with	   N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1.13	   Upon	  
addition	  of	  s-­‐BuLi	  to	  12	  in	  THF	  at	  –78	  °C	  (νC=O	  1694	  cm
-­‐1),	  
lithiation	  proceeded	  to	  give	  lithiated	  intermediate	  13	  (νC=O	  
1645	  cm-­‐1).	  However,	  after	  2	  h	  the	  reaction	  was	  incomplete	  
(Scheme	   6).	   Conversely,	   lithiation	   using	   s-­‐BuLi/TMEDA	  
in	  Et2O	  at	  –78	  °C	  was	  much	  faster:	  12	  (νC=O	  1700	  cm
-­‐1)	  was	  
converted	   in	   to	   lithiated	   intermediate	   15	   (νC=O	   1644	  cm
-­‐1)	  
via	   pre-­‐lithiation	   complex	   14	   (νC=O	   1681	   cm
-­‐1)17	   within	   15	  
min	  (Scheme	  6).	  
Scheme	  6.	  In	  situ	  IR	  Spectroscopic	  Monitoring	  of	  the	  
Lithiation	  of	  N-­‐Boc	  Piperazine	  12	  
	  	  	  
Due	   to	   the	   shorter	   lithiation	   time	   and	   associated	   opera-­‐
tional	  ease,	  we	  opted	  to	  perform	  lithiation/trapping	  reac-­‐
tions	  of	  the	  sterically	  hindered	  N-­‐Boc-­‐N’-­‐tert-­‐butyl	  piper-­‐
azine	   12	   and	   N-­‐Boc-­‐N’-­‐cumyl	   piperazine	   16	   using	   s-­‐
BuLi/TMEDA	  in	  Et2O	  at	  –78	  °C	  for	  1	  h.	  Exposure	  of	  either	  
12	  or	  16	  to	  these	  conditions	  followed	  by	  trapping	  led	  to	  α-­‐
substituted	   piperazines	   17	   and	   18	   in	   45-­‐98%	   yields	  
(Scheme	   7).	   Since	  we	  were	   unsuccessful	   in	   our	   attempts	  
to	   cleave	   the	   N-­‐tert-­‐butyl	   group	   we	   focused	   mostly	   on	  
cumyl	   protected	   piperazine	   16	   as	   it	   can	   be	   removed	   by	  
hydrogenolysis.13	   Silylated,	   stannylated	   and	   methylated	  
piperazines	   18a,	   18b	   and	   18c	   were	   isolated	   in	   98%,	   80%	  
and	   95%	   yield	   respectively.	   Transmetallation	   to	   copper	  
followed	   by	   trapping	   with	   allyl	   bromide15a,17	   gave	   α-­‐allyl	  
piperazine	  18d	  in	  80%	  yield.	  Lithiation/trapping	  of	  16	  and	  
12	   with	   methyl	   chloroformate	   resulted	   in	   methyl	   esters	  
18e	   and	   17a	   in	   66%	   and	   45%	   yields.	   Trapping	   16	   with	  
paraformaldehyde	   gave	   a	   mixture	   of	   oxazolidinone	   18f	  
and	  alcohol	  18g	   in	  26%	  and	  57%	  yield.	  Use	  of	  cyclohexa-­‐
none	   gave	   solely	   oxazolidinone	   18h	   in	   58%	   yield.	   Trap-­‐
ping	  of	  16	  with	  benzophenone	  gave	  18i	  and	  18j	   in	  a	  total	  
yield	   of	   97%,	   whereas	   trapping	   of	   12	   gave	   only	   oxazoli-­‐
dinone	  17b	  in	  57%	  yield.	  Importantly,	  no	  ring	  fragmented	  
side-­‐products	  were	  observed	  in	  any	  case	  (due	  to	  the	  steri-­‐
cally	  demanding	  N-­‐substituent),	  and	  the	  cumyl	  protecting	  
group	  can	  be	  easily	  removed	  by	  hydrogenolysis.13	  Interest-­‐
ingly,	  for	  the	  same	  electrophile,	  the	  yields	  with	  N-­‐Boc-­‐N’-­‐
cumyl	   piperazine	   16	   (Scheme	   7)	   were	   higher	   than	  when	  
using	  N-­‐Boc-­‐N’-­‐benzyl	  piperazine	  1	  (Scheme	  3).	  It	   is	  pos-­‐
sible	  that	  the	   larger	  protecting	  group	  prevents	  unwanted	  
coordination	  of	  the	  distal	  nitrogen	  to	  the	  electrophiles.	  
	  
Scheme	   7.	   Lithiation/Trapping	   of	  N-­‐Boc	   Piperazines	  
12	  and	  16	  	  
	  
One	   of	   the	   most	   useful	   extensions	   to	   the	   lithia-­‐
tion/trapping	  of	  N-­‐Boc	  heterocycles	  for	  synthetic	  applica-­‐
tions	   is	   the	  α-­‐arylation	  methodology	  developed	  by	  Cam-­‐
pos	   and	   co-­‐workers.18	   This	   process	   proceeds	   via	   Li/Zn	  
transmetallation	   and	   subsequent	   Negishi	   cross-­‐coupling	  
and	  has	  been	  well	   studied	  using	  N-­‐Boc	  pyrrolidine19	   and	  
piperidine.16b,20	   In	   2010,	   our	   group	   reported	   the	   only	   ex-­‐
ample	  with	  an	  N-­‐Boc	  piperazine.15c	  Therefore	  we	  decided	  
to	   explore	   the	   arylation	   reaction	   using	   our	   diamine	   free	  
 
conditions,	   since	   TMEDA	   was	   known	   to	   hinder	   the	  
Negishi	  coupling.	  	  
After	   lithiation,	   N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1	   under-­‐
went	  Li/Zn	   transmetallation	  with	  ZnCl2,	   prior	   to	  Negishi	  
coupling	  with	  bromobenzene,	  catalysed	  by	  Pd(OAc)2	  and	  
tBu3PH
+BF4
-­‐.	   Surprisingly,	   a	   33:67	  mixture	   of	   inseparable	  
regioisomers	  19	  and	  20	  was	  obtained	  in	  a	  combined	  42%	  
yield	   (Scheme	  8).	   Formation	  of	   the	  unexpected	   regioiso-­‐
mer	  20	   presumably	   occurs	   through	   a	   β-­‐hydride	   elimina-­‐
tion/insertion	   sequence	  of	   the	   intermediate	  organopalla-­‐
dium	  species.20c,21	  This	  result	  corrects	  our	  previous	   incor-­‐
rect	   report	   that	   only	   19	   was	   formed.15c	  A	   catalyst/ligand	  
screen	   was	   performed	   in	   an	   attempt	   to	   selectively	   form	  
either	  α-­‐	  or	  β-­‐arylated	  N-­‐Boc	  piperazines	  (see	  Supporting	  
Information	   for	   full	  details).	  Use	  of	  PEPPSI-­‐iPr22	   resulted	  
in	   near	   complete	   selectivity	   for	   β-­‐arylation	   with	   a	   5:95	  
mixture	   of	   19	   and	   20	   being	   isolated	   in	   a	   moderate	   38%	  
yield	  (Scheme	  8).	  
	  	  
Scheme	  8.	  Arylation	  of	  N-­‐Boc	  piperazines	  1	  and	  16	  	  	  
 
Submitting	  N-­‐Boc-­‐N’-­‐cumyl	   piperazine	   16	   to	   arylation	  
catalyzed	  by	  Pd(dba)2	   and	  RuPhos	   resulted	   in	   formation	  
of	   only	   the	   α-­‐arylated	   piperazine	   21	   in	   15%	   yield,	   along	  
with	  ring-­‐fragmentation	  side-­‐product	  22	  which	  was	  isola-­‐
ted	   in	  30%	  yield	   (Scheme	  8).	  Thus,	   selective	  synthesis	  of	  
both	   the	   α-­‐	   and	   β-­‐arylated	   piperazines	   can	   be	   achieved	  
through	   substrate	   control	   by	   varying	   the	   distal	   nitrogen	  
protecting	  group	  and	  catalyst	   system.	  These	   initial	  preli-­‐
minary	  results	  are	  encouraging	  and	  could	  warrant	  further	  
investigation.	  
In	  conclusion,	  we	  have	  developed	  unifying,	  simple	  and	  
general	  procedures	   for	   the	   racemic	   lithiation/trapping	  of	  
N-­‐Boc	  piperazines.	  In	  situ	  IR	  spectroscopic	  methods	  were	  
used	   to	  determine	   the	  optimum	  conditions	   for	   lithiation	  
of	  substrates	  with	  both	  sterically	  small	  (benzyl)	  and	  large	  
(cumyl)	   substituents.	   The	   previous	   complicated	   and	   di-­‐
verse	  literature	  procedures	  have	  been	  simplified,	  resulting	  
an	   easy	   diamine-­‐free	   lithiation/trapping	   of	   N-­‐Boc-­‐N-­‐
benzyl	   piperazine	   1	   and	   a	   slightly	  more	   complicated	   but	  
higher	   yielding	   lithiation/trapping	   of	  N-­‐Boc-­‐N-­‐cumyl	   pi-­‐
perazine	  16.	  These	  methods	  represent	  much	  needed	  sim-­‐
ple	   and	   general	   approaches	   for	   the	   direct	   racemic	   func-­‐
tionalization	   of	   piperazines,	   and	   will	   find	   use	   in	   early-­‐
stage	  medicinal	  chemistry	  programmes.	  Additionally,	  the	  
selective	  formation	  of	  both	  α-­‐	  and	  β-­‐arylated	  piperazines	  
has	  been	  discovered.	  
Experimental	  Section	  
All-­‐non	  aqueous	  reactions	  were	  carried	  out	  under	  oxy-­‐
gen	   free	  Ar	   or	  N2	   using	   flame-­‐dried	   glassware.	   Et2O	  and	  
THF	   were	   freshly	   distilled	   from	   sodium	   and	   benzophe-­‐
none.	   Alkyllithiums	   were	   titrated	   against	   N-­‐
benzylbenzamide	   before	   use.	   TMEDA	   was	   distilled	   over	  
CaH2	  before	  use.	  Petrol	  refers	  to	  the	  fraction	  of	  petroleum	  
ether	  boiling	  in	  the	  range	  40-­‐60	  °C	  and	  was	  purchased	  in	  
Winchester	  quantities.	  Water	  is	  distilled	  water.	  
Flash	   column	   chromatography	   was	   carried	   out	   using	  
Fluka	   Chemie	   GmbH	   silica	   (220-­‐440	   mesh).	   Thin	   layer	  
chromatography	   was	   carried	   out	   using	   commercially	  
available	  Merck	  F254	  aluminium	  backed	  silica	  plates.	  Pro-­‐
ton	   (400	   MHz)	   and	   carbon	   (100.6	   MHz)	   NMR	   spectra	  
were	   recorded	   on	   a	   Jeol	   ECX-­‐400	   instrument	   using	   an	  
internal	  deuterium	   lock.	   For	   samples	   recorded	   in	  CDCl3,	  
chemical	  shifts	  are	  quoted	  in	  parts	  per	  million	  relative	  to	  
CHCl3	  (δH	  7.26)	  and	  CDCl3	  (δC	  77.0,	  central	  line	  of	  triplet).	  
Carbon	  NMR	  spectra	  were	  recorded	  with	  broad	  band	  pro-­‐
ton	   decoupling	   and	   assigned	   using	   DEPT	   experiments.	  
Coupling	   constants	   (J)	   are	   quoted	   in	   Hertz.	   Melting	  
points	   were	   carried	   out	   on	   a	   Gallenkamp	  melting	   point	  
apparatus.	  Boiling	  points	  give	  for	  compounds	  purified	  by	  
Kügelrohr	   distillation	   correspond	   to	   the	   oven	   tempera-­‐
ture	  during	  distillation.	  Infrared	  spectra	  were	  recorded	  on	  
an	  ATI	  Mattson	  Genesis	   FT-­‐IR	   spectrometer	   or	   a	   Perkin	  
Elmer	  UATR	  Two	  FT-­‐IR	   spectrometer.	   Electrospray	  high	  
and	   low	   resonance	  mass	   spectra	   were	   recorded	   at	   room	  
temperature	   on	   a	   Bruker	   Daltronics	   microOTOF	   spec-­‐
trometer.	   In	   situ	   ReactIR™	   infra-­‐red	   spectroscopic	  moni-­‐
toring	   was	   performed	   on	   a	   Mettler-­‐Toledo	   ReactIR	   iC10	  
spectrometer	  with	  a	  silicon-­‐tipped	  (SiComp)	  probe.	  
Diamine	   Free	   Lithiation/Trapping	   of	   N-­‐Boc-­‐N’-­‐
Benzyl	  Piperazine	   1.	   s-­‐BuLi	   (1.3	  M	   solution	   in	  hexanes,	  
1.3	  eq.)	  was	  added	  dropwise	  to	  a	  stirred	  solution	  of	  N-­‐Boc-­‐
N’-­‐Benzyl	  Piperazine	  1	  (1.0-­‐3.0	  mmol,	  1.0	  eq.)	  in	  THF	  (0.14	  
M)	  at	  –78	  °C	  under	  Ar.	  The	  resulting	  solution	  was	  stirred	  
at	  –78	  °C	  for	  1	  h.	  Then	  the	  electrophile	  (2.0	  eq.)	  was	  added	  
dropwise,	   as	   a	   solution	   in	   THF	   (1	  mL)	   if	   necessary.	   The	  
reaction	  mixture	  was	  stirred	  at	  –78	  °C	  for	  15	  min	  and	  then	  
allowed	   to	   warm	   to	   rt	   over	   30	   min.	   Then,	   saturated	  
NH4Cl(aq)	  (10	  mL),	  20%	  NaOH(aq)	  (10	  mL)	  and	  Et2O	  (10	  mL)	  
were	  added	  and	  the	  two	  layers	  were	  separated.	  The	  aque-­‐
ous	   layer	  was	  extracted	  with	  Et2O	  (3	  ×	  10	  mL).	  The	  com-­‐
bined	   organic	   layers	   were	   dried	   (MgSO4),	   filtered	   and	  
evaporated	   under	   reduced	   pressure	   to	   give	   the	   crude	  
product	  which	  was	  purified	  by	   flash	   column	  chromatog-­‐
raphy	  on	  silica	  gel.	  	  
	  	  	  tert-­‐Butyl	   4-­‐benzyl-­‐2-­‐(trimethylsilyl)piperazine-­‐1-­‐
carboxylate	   (3a).	  N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1	   (276	   mg,	  
1.0	  mmol),	   s-­‐BuLi	   (1.3	  M	   solution	   in	   hexanes,	   1.0	  mL,	   1.3	  
mmol)	  and	  Me3SiCl	  (254	  µL,	  2.0	  mmol)	  gave,	  after	  purifi-­‐
cation	  (SiO2,	  9:1	  petrol-­‐EtOAc),	  substituted	  piperazine	  3a	  
(236	  mg,	   68%)	   as	   a	   colourless	   oil;	  RF	   (9:1	   petrol-­‐EtOAc)	  
0.4;	   1H	  NMR	   (400	  MHz,	   CDCl3)	   (60:40	  mixture	   of	   rota-­‐
mers)	   δ	   7.32-­‐7.30	   (m,	   4H),	   7.27-­‐7.22	   (m,	   1H)	   4.20	   (br	   s,	  
 
0.6H),	  3.80	  (br	  s,	  0.4H),	  3.61-­‐3.55	  (m,	  1H),	  3.44	  (d,	  J	  =	  13.0	  
Hz,	  1H),	  3.40	  (d,	  J	  =	  13.0	  Hz,	  1H),	  3.05	  (br	  s,	  0.4H),	  2.92	  (br	  
s,	  0.6H),	  2.80	  (d,	  J	  =	  12.0	  Hz,	  1H),	  2.72	  (m,	  0.6H),	  2.64	  (br	  
s,	  0.4H),	  2.24	  (br	  s,	  1H),	  1.93	  (td,	  J	  =	  12.0,	  3.0	  Hz,	  1H),	  1.46	  
(s,	  9H),	  0.12	  (s,	  9H);	   13C	  NMR	  (100.6	  MHz,	  CDCl3)	  δ	  154.7,	  
138.3,	  129.1,	  128.1,	  127.0,	  79.1,	  63.4,	  54.3,	  53.2,	  45.3,	  41.4,	  28.4,	  
–0.8;	  IR	  (CHCl3)	  2977,	  2804,	  1673	  (C=O),	  1454,	  1420,	  1366,	  
1296,	   1168,	   1111,	   1027,	  840	  cm–1;	  HRMS	  (ESI)	  m/z	  calcd	   for	  
C19H33N2O2Si	  (M+H)
+	  349.2306,	  found	  349.2297	  (+1.7	  ppm	  
error).	  Spectroscopic	  data	  consistent	  with	  those	  reported	  
in	  the	  literature.13	  
	  tert-­‐Butyl	   4-­‐benzyl-­‐2-­‐(tributylstannyl)piperazine-­‐1-­‐
carboxylate	   (3b).	  N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1	   (276	  mg,	  
1.0	  mmol),	   s-­‐BuLi	   (1.3	  M	   solution	   in	   hexanes,	   1.0	  mL,	   1.3	  
mmol)	  and	  Bu3SnCl	  (542	  µL,	  2.0	  mmol)	  gave,	  after	  purifi-­‐
cation	  (SiO2,	  19:1	  petrol-­‐EtOAc),	  substituted	  piperazine	  3b	  
(387	  mg,	   68%)	   as	   a	   colourless	   oil;	  RF	   (9:1	   petrol-­‐EtOAc)	  
0.2;	   1H	   NMR	   (400	   MHz,	   CDCl3)	   (50:50	   mixture	   of	   rota-­‐
mers)	  δ	  7.38-­‐7.21	  (m,	  5H),	  4.13	  (s,	  0.5H),	  4.03	  (br	  d,	  J	  =	  13.0	  
Hz,	  0.5H),	  3.80-­‐3.16	  (m,	  4H),	  2.82-­‐2.37	  (m,	  3H),	  2.21	  (br	  s,	  
0.5H),	   1.96-­‐1.80	  (m,	  0.5H),	   1.55-­‐1.35	  (m,	   15H),	   1.35-­‐1.23	  (m,	  
6H),	   0.99-­‐0.78	   (m,	   15H);	   13C	   NMR	   (100.6	   MHz,	   CDCl3)	  
(mixture	   of	   rotamers)	   δ	   154.6,	   154.2,	   138.2,	   129.4,	   128.3,	  
127.2,	  79.5,	  79.4,	  63.3,	  58.1,	  53.2,	  53.0,	  46.5,	  45.5,	  44.8,	  42.6,	  
29.3,	  29.3,	  28.5,	  27.9,	  27.7,	   13.8,	   11.1,	   10.4;	   IR	   (CHCl3)	  2961,	  
2911,	   2881,	   2827,	   1647	   (C=O),	   1433,	   1395,	   1395,	   1344,	   1278,	  
1231,	  1151,	  1088,	  1055,	  1007,	  850,	  688	  cm–1;	  HRMS	  (ESI)	  m/z	  
calcd	   for	  C28H51N2O2Sn	   (M+H)
+	   567.2972,	   found	  567.2945	  
(+3.9	   ppm	   error).	   Spectroscopic	   data	   consistent	   with	  
those	  reported	  in	  the	  literature.13	  
tert-­‐Butyl	   4-­‐benzyl-­‐2-­‐methylpiperazine-­‐1-­‐carboxylate	  
(3c).	  N-­‐Boc-­‐N’-­‐benzyl	  piperazine	  1	  (829	  mg,	  3.0	  mmol),	  s-­‐
BuLi	   (1.3	  M	   solution	   in	   hexanes,	   3.0	  mL,	   3.9	  mmol)	   and	  
MeI	  (374	  µL,	  6.0	  mmol)	  gave,	  after	  purification	  (SiO2,	  9:1	  
petrol-­‐EtOAc),	   substituted	   piperazine	   3c	   (645	   mg,	   74%)	  
as	  a	  colourless	  oil;	  RF	  (7:3	  petrol-­‐EtOAc)	  0.6;	  
1H	  NMR	  (400	  
MHz,	  CDCl3)	  δ	  7.36-­‐7.29	   (m,	  4H),	   7.26-­‐7.22	   (m,	   1H),	   4.18	  
(br	  s,	  1H),	  3.80	  (br	  d,	  J	  =	  12.5	  Hz,	  1H),	  3.53	  (d,	  J	  =	  13.0	  Hz,	  
1H),	  3.40	  (d,	  J	  =	  13.0	  Hz,	  1H),	  3.11	  (td,	  J	  =	  12.5,	  3.5	  Hz,	  1H),	  
2.77-­‐2.73	  (m,	  1H),	  2.59	  (dt,	  J	  =	  11.0,	  1.5	  Hz,	  1H),	  2.12	  (dd,	  J	  =	  
11.0,	  4.0	  Hz,	  1H),	  2.00	  (ddd,	  J	  =	  12.5,	  11.5,	  3.5	  Hz,	  1H),	  1.45	  (s,	  
9H),	  1.24	  (d,	  J	  =	  6.5	  Hz,	  3H);	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  
δ	  154.8,	  138.4,	  128.7,	  128.2,	  127.0,	  79.3,	  62.8,	  57.3,	  53.2,	  47.0,	  
39.1,	   28.4,	   15.9;	   IR	   (ATR)	   2973,	   1688	   (C=O),	   1452,	   1407,	  
1392,	  1364,	  1341,	  1322,	  1305,	  1279,	  1247,	  1223,	  1158,	  1107,	  1059,	  
1039,	   1028,	   740,	   700	   cm-­‐1;	   HRMS	   (ESI)	   m/z	   calcd	   for	  
C17H27N2O2	   (M+H)
+	   291.2067,	   found	   291.2072	   (–1.0	   ppm	  
error).	  Spectroscopic	  data	  consistent	  with	  those	  reported	  
in	  the	  literature.13	  
1-­‐tert-­‐Butyl	   2-­‐methyl	   4-­‐benzylpiperazine-­‐1,2-­‐
dicarboxylate	  (3d).	  N-­‐Boc-­‐N’-­‐benzyl	  piperazine	  1	  (276	  mg,	  
1.0	  mmol),	   s-­‐BuLi	   (1.3	  M	   solution	   in	   hexanes,	   1.0	  mL,	   1.3	  
mmol)	  and	  MeOCOCl	  (155	  µL,	  2.0	  mmol)	  gave,	  after	  puri-­‐
fication	  (SiO2,	  9:1	  to	  7:3	  petrol-­‐EtOAc),	  substituted	  piper-­‐
azine	  3d	  (200	  mg,	  60%)	  as	  a	  colourless	  oil;	  RF	  (7:3	  petrol-­‐
EtOAc)	  0.7;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  (55:45	  mixture	  of	  
rotamers)	  δ	  7.32-­‐7.24	  (m,	  5H),	  4.71	  (br	  s,	  0.55H),	  4.54	  (br	  s,	  
0.45H),	   3.85	   (br	   d,	   J	   =	   13.0	   Hz,	   0.55H),	   3.77-­‐3.75	   (m,	  
0.45H),	  3.73	  (s,	  1.35H),	  3.71	  (s,	  1.65H),	  3.58	  (d,	  J	  =	  13.0	  Hz,	  
0.45H),	   3.58	   (d,	   J	   =	   13.0	  Hz,	   0.55H),	   3.45	   (d,	   J	   =	   13.0	  Hz,	  
0.55H),	   3.41	   (d,	   J	  =	   13.0	  Hz,	  0.45H),	   	   3.34-­‐3.27	   (m,	   1.55H),	  
3.18	   (td,	   J	   =	   13.0,	   	   3.0	  Hz,	   0.45H),	   2.79	   (br	   d,	   J	   =	   11.0	  Hz,	  
0.45H),	  2.74	  (d,	  J	  =	  11.0	  Hz,	  0.55H),	  2.18	  (td,	  J	  =	  11.0,	  4.0	  Hz,	  
1H),	   2.11	   (br	   d,	   J	   =	   11.0	  Hz,	   0.55H),	   2.11	   (br	   d,	   J	   =	   11.0	  Hz,	  
0.45H),	  1.47	  (s,	  4.9H),	  1.42	  (s,	  4.1H);	   13C	  NMR	  (100.6	  MHz,	  
CDCl3)	   (mixture	   of	   rotamers)	   δ	   171.3,	   171.1,	   155.8,	   155.3,	  
137.6,	   128.7,	   128.1,	   127.2,	   80.2,	   62.3,	   55.5,	   54.3,	   53.5,	   52.4,	  
52.3,	   51.9,	   42.0,	   41.0,	   28.3;	   IR	   (CHCl3)	   2979,	   1744	   (C=O,	  
CO2Me),	  1691	  (C=O,	  Boc),	  1408,	  1366,	  1301,	  1169,	  1119,	  1046,	  
976,	   867	   cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C18H27N2O4	  
(M+H)+	   335.1965,	   found	   335.1974	   (–2.7	   ppm	   error).	   Spec-­‐
troscopic	  data	  consistent	  with	  those	  reported	  in	  the	  liter-­‐
ature.13	  
tert-­‐Butyl	   4-­‐benzyl-­‐2-­‐(hydroxymethyl)piperazine-­‐1-­‐
carboxylate	   (3e).	  N-­‐Boc-­‐N’-­‐benzyl	   piperazine	   1	   (276	   mg,	  
1.0	  mmol),	   s-­‐BuLi	   (1.3	  M	   solution	   in	   hexanes,	   1.0	  mL,	   1.3	  
mmol)	   and	   paraformaldehyde	   (60	   mg,	   2.0	   mmol)	   gave,	  
after	  purification	  (SiO2,	  7:3	  to	  1:1	  petrol-­‐EtOAc),	  substitut-­‐
ed	  piperazine	  3e	   (197	  mg,	  64%)	  as	  a	  colourless	  oil;	  RF	  (1:1	  
petrol-­‐EtOAc)	  0.2;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.36-­‐7.24	  
(m,	  5H),	  4.07	  (br	  s,	  1H),	  3.96-­‐3.81	  (m,	  3H),	  3.51	  (d,	  J	  =	  13.0	  
Hz,	  1H),	  3.47	  (d,	  J	  =	  13.0	  Hz,	  1H),	  3.40	  (br	  s,	  1H),	  2.98	  (dt,	  J	  
=	  11.5,	  2.0	  Hz,	  1H),	  2.83	  (br	  d,	  J	  =	  10.0	  Hz,	  1H),	  2.31	  (ddd,	  J	  =	  
11.5,	  4.0,	   1.0	  Hz,	   1H),	  2.09	   (ddd,	   J	  =	   12.5,	   11.5,	  4.0	  Hz,	   1H),	  
1.45	   (s,	   3H),	   OH	   not	   resolved;	   13C	   NMR	   (100.6	   MHz,	  
CDCl3)	   δ	   155.1,	   137.0,	   129.0,	   128.5,	   127.5,	   80.0,	   66.7,	   63.0,	  
55.1,	  52.5,	  51.1,	  41.4,	  28.4;	  IR	  (CHCl3)	  3280	  (OH),	  2971,	  2913,	  
2781	  1658	  (C=O),	  1433,	  1390,	  1345,	  1302,	  1197,	  1152,	  1103,	  1060,	  
1035,	  997,	  743	  cm–1;	  HRMS	  (ESI)	  m/z	  calcd	  for	  C17H27N2O3	  
(M+H)+	   307.2016,	   found	  307.2023	   (–2.2	  ppm	  error).	  Spec-­‐
troscopic	  data	  consistent	  with	  those	  reported	  in	  the	  liter-­‐
ature.23	  
7-­‐Benzyl-­‐hexahydrospiro[[1,3]oxazolo[3,4-­‐a]piperazine-­‐
1,1'-­‐cyclohexane]-­‐3-­‐one	   (3f).	  N-­‐Boc-­‐N’-­‐benzyl	  piperazine	   1	  
(276	  mg,	  1.0	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  1.0	  
mL,	   1.3	   mmol)	   and	   cyclohexanone	   (207	   µL,	   2.0	   mmol)	  
gave,	   after	   purification	   (SiO2,	   1:1	   petrol-­‐EtOAc),	   oxazoli-­‐
dinone	   3f	   (131	   mg,	   44%)	   as	   a	   white	   solid;	   RF	   (1:1	   petrol-­‐
EtOAc)	   0.1;	   mp	   64-­‐66	   °C;	   1H	  NMR	   (400	  MHz,	   CDCl3)	   δ	  
7.35-­‐7.25	  (m,	  5H),	  3.76	  (dd,	   J	  =	   13.0,	  3.5	  Hz,	   1H),	  3.61-­‐3.49	  
(m,	  2H),	  3.39	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  3.05	  (td,	  J	  =	  12.5,	  3.5	  
Hz,	  1H),	  2.77-­‐2.73	  (m,	  2H),	  2.05-­‐1.97	  (m,	  2H),	  1.89-­‐1.20	  (m,	  
10H);	   13C	   NMR	   (100.6	   MHz,	   CDCl3)	   δ	   156.4,	   137.3,	   128.8,	  
128.3,	  127.3,	  80.7,	  63.0,	  61.7,	  52.8,	  51.7,	  41.0,	  36.7,	  30.7,	  28.3,	  
25.0,	   21.9;	   IR	   (CHCl3)	   2896,	   1710	   (C=O),	   1428,	   1331,	   1286,	  
1074,	   1025,	  961,	   890,	   745	   cm–1;	  HRMS	   (ESI)	  m/z	   calcd	   for	  
C18H25N2O2	   (M+H)
+	   301.1905,	   found	  301.1911	   (+1.6	  ppm	  er-­‐
ror).	  
7-­‐Benzyl-­‐1,1-­‐diphenyl-­‐hexahydro-­‐1H-­‐[1,3]oxazolo[3,4-­‐
a]piperazin-­‐3-­‐one	  (3g).	  N-­‐Boc-­‐N’-­‐benzyl	  piperazine	  1	  (415	  
mg,	   1.5	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	   1.5	  mL,	  
1.95	   mmol)	   and	   benzophenone	   (547	   mg,	   3.0	   mmol)	   in	  
THF	  (1	  mL)	  gave,	  after	  purification	  (SiO2,	  4:1	  to	  7:3	  petrol-­‐
EtOAc),	   substituted	   piperazine	   3g	   (520	   mg,	   90%)	   as	   a	  
white	   solid,	  RF	   (7:3	   petrol-­‐EtOAc)	   0.2;	  mp	   146-­‐149	   °C;	  
1H	  
NMR	  (400	  MHz,	  CDCl3)	  δ	  7.53-­‐7.50	  (m,	  2H),	  7.40-­‐7.21	  (m,	  
13H),	  4.54	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  3.80	  (ddd,	  J	  =	  13.0,	  3.5,	  
1.5	  Hz,	   1H),	   3.50	   (d,	   J	   =	   13.0	  Hz,	   1H),	   3.31	   (d,	   J	   =	   13.0	  Hz,	  
 
1H),	  3.09	  (ddd,	  J	  =	  13.0,	  12.0,	  3.5	  Hz,	  1H),	  2.70-­‐2.66	  (m,	  1H),	  
2.55	  (ddd,	  J	  =	  11.0,	  3.5,	  1.5	  Hz,	  1H),	  1.93	  (td,	  J	  =	  12.0,	  3.5	  Hz,	  
1H),	  1.57	  (t,	  J	  =	  11.0	  Hz,	  1H);	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  δ	  
156.5,	  142.7,	  139.1,	  137.6,	  129.1,	  128.8,	  128.7,	  128.6,	  128.5,	  128.1,	  
127.6,	   126.2,	   126.0,	   85.3,	   62.9,	   61.1,	   55.7,	   50.7,	   41.5;	   IR	  
(CHCl3)	   3020,	   2400,	   1751	   (C=O),	   1422,	   1215,	   929,	   759,	   669	  
cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C25H25N2O2	   (M+H)
+	  
385.1911,	   found	   385.1899	   (+3.6	   ppm	   error).	   Spectroscopic	  
data	  consistent	  with	  those	  reported	  in	  the	  literature.13	  
tert-­‐Butyl	  4-­‐methylpiperazine-­‐1-­‐carboxylate	  (4).	  A	  solu-­‐
tion	   of	   di-­‐tert-­‐butyl	   dicarbonate	   (21.6	   g,	   99.2	   mmol,	   1.1	  
eq.)	   in	   CH2Cl2	   (50	  mL)	   was	   added	   dropwise	   to	   a	   stirred	  
solution	   of	  N-­‐methyl	   piperazine	   (10	   mL,	   90.2	   mmol,	   1.0	  
eq.)	   in	   CH2Cl2	   (150	  mL)	   at	   0	   °C	   under	   Ar.	   The	   resulting	  
solution	  was	  allowed	  to	  warm	  to	  rt	  and	  stirred	  for	  at	  rt	  for	  
16	   h.	  Water	   (100	  mL)	   and	   20%	  NaOH(aq)	   (100	  mL)	   were	  
added	   and	   the	   layers	   separated.	   The	   aqueous	   layer	   was	  
extracted	  with	  CH2Cl2	  (3	  ×	  100	  mL).	  The	  combined	  organ-­‐
ic	  layers	  were	  dried	  (MgSO4),	  filtered	  and	  evaporated	  un-­‐
der	  reduced	  pressure	  to	  give	  the	  crude	  product.	  Purifica-­‐
tion	   by	   Kugelrohr	   distillation	   gave	   N-­‐Boc-­‐N′-­‐methyl	   pi-­‐
perazine	  4	  (16.5	  g,	  92%)	  as	  a	  colourless	  oil,	  RF	  (9:1	  CH2Cl2-­‐
MeOH)	   0.2;	   bp	   105-­‐110	   °C	   /	   0.9	   mmHg;	   1H	   NMR	   (400	  
MHz,	  CDCl3)	  δ	  3.39	  (t,	  J	  =	  5.0	  Hz,	  4H),	  2.29	  (t,	  J	  =	  5.0	  Hz,	  
4H),	  2.24	  (s,	  3H),	  1.41	  (s,	  9H).	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  
δ	  154.6,	  79.5,	  54.7,	  46.1,	  43.5,	  28.3.	  Spectroscopic	  data	  con-­‐
sistent	  with	  those	  reported	  in	  the	  literature.24	  
tert-­‐Butyl	   N-­‐ethenyl-­‐N-­‐[2-­‐
(methylamino)ethyl]carbamate	   (5).	   N-­‐Boc-­‐N’-­‐methyl	   pi-­‐
perazine	  4	   (200	  mg,	   1.0	  mmol),	  s-­‐BuLi	   (1.3	  M	  solution	   in	  
hexanes,	   1.0	   mL,	   1.3	   mmol)	   and	   Me3SiCl	   (254	   µL,	   2.0	  
mmol)	   gave,	   after	   purification	   (SiO2,	   9:1	   CH2Cl2-­‐MeOH),	  
vinyl	  carbamate	  5	  (60	  mg,	  30%)	  as	  a	  pale	  yellow	  oil,	  RF	  (9:1	  
CH2Cl2-­‐MeOH)	  0.1;	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.01	  (br	  
s,	   1H),	  4.35	  (d,	   J	  =	   16.0	  Hz,	   1H),	  4.21	  (br	  s,	   1H),	  3.65	  (br	  s,	  
2H),	   2.79	   (t,	   J	   =	   7.0	  Hz,	   2H),	   2.47	   (s,	   3H),	   2.11	   (br	   s,	   1H),	  
1.49	   (s,	   9H);	   13C	  NMR	   (100.6	  MHz,	   CDCl3)	   δ	   152.9,	   132.9,	  
90.8,	   81.3,	   48.2,	   41.9,	   36.0,	   28.2;	   IR	   (CHCl3)	   3513	   (NH),	  
2978,	   1698	   (C=O),	   1629,	   1456,	   1368,	   1152,	   862,	   759	   cm–1;	  
HRMS	   (ESI)	  m/z	   calcd	   for	   C10H21N2O2	   (M+H)
+	   201.1598,	  
found	  201.1595	  (+2.0	  ppm	  error).	  	  	  
tert-­‐Butyl	   N-­‐ethenyl-­‐N-­‐{2-­‐
[(methoxycarbonyl)(methyl)amino]ethyl}carbamate	   (7)	  
and	   methyl	   2-­‐{[(tert-­‐butoxy)carbonyl]({2-­‐
[(methoxycarbonyl)(methyl)amino]ethyl})amino}prop-­‐2-­‐
enoate	   (8).	   N-­‐Boc-­‐N’-­‐methyl	   piperazine	   4	   (200	   mg,	   1.0	  
mmol),	   s-­‐BuLi	   (1.3	   M	   solution	   in	   hexanes,	   1.0	   mL,	   1.3	  
mmol)	  and	  MeOCOCl	  (155	  µL,	  2.0	  mmol)	  gave,	  after	  puri-­‐
fication	   (SiO2,	   9:1	   CH2Cl2-­‐MeOH),	   vinyl	   carbamate	   7	   (88	  
mg,	  34%)	  as	  a	  colourless	  oil,	  RF	  (7:3	  petrol-­‐EtOAc)	  0.4;	  
1H	  
NMR	  (400	  MHz,	  CDCl3)	  (50:50	  mixture	  of	  rotamers)	  δ	  7.11	  
(dd,	   J	   =15.0,	   10.0	   Hz,	   0.5H),	   6.95	   (dd,	   J	   =	   15.0,	   10.0	   Hz,	  
0.5H),	   4.48	   (m,	   0.5H),	   4.46-­‐4.18	   (m,	   1.5H),	   3.69	   (s,	   3H),	  
3.69-­‐3.57	  (m,	  2H),	  3.39-­‐3.35	  (m,	  2H),	  2.93	  (s,	  1.5H),	  2.91	  (s,	  
1.5H),	  1.50	  (s,	  9H);	   13C	  NMR	  (100.6	  MHz,	  CDCl3)	  (mixture	  
of	   rotamers)	   δ	   156.6,	   152.9,	   152.5,	   132.9,	   132.6,	   91.1,	   90.6,	  
81.4,	   81.2,	   52.6,	   52.5,	   45.9,	   45.6,	   41.2,	   40.4,	   35.5,	   28.1;	   IR	  
(CHCl3)	   2983,	   1697	   (C=O),	   1630	   (C=O),	   1486,	   1423,	   1393,	  
1368,	   1233,	   1216,	   1155,	   575	   cm–1;	  HRMS	   (ESI)	  m/z	   calcd	   for	  
C12H22N2NaO4	  (M+Na)
+	  281.1476,	  found	  281.1472	  (–1.0	  ppm	  
error);	  and	  vinyl	  carbamate	  8	  (35	  mg,	  11%)	  as	  a	  colourless	  
oil,	  RF	  (7:3	  petrol-­‐EtOAc)	  0.2;	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  
(50:50	  mixture	   of	   rotamers)	   δ	   5.92	   (br	   s,	   1H),	   5.56	   (br	   s,	  
0.5H),	  5.40	   (br	   s,	  0.5H),	   3.78	   (s,	   1.5H),	   3.77	   (s,	   1.5H),	   3.67	  
(s,	  3H),	  3.62-­‐3.55	  (m,	  2H),	  3.48-­‐3.45	  (m,	  2H),	  3.95	  (s,	  1.5H),	  
3.94	  (s,	  1.5H),	  1.41	  (br	  s,	  9H);	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  
(mixture	   of	   rotamers)	   δ	   166.2,	   157.0,	   156.7,	   153.7,	   153.6,	  
140.5,	  140.0,	  117.7,	  81.4,	  81.2,	  52.6,	  52.5,	  52.3,	  52.2,	  47.9,	  47.1,	  
35.2,	  34.8,	  28.0;	  IR	  (CHCl3)	  3023,	  1734	  (C=O,	  CO2Me),	  1699	  
(C=O,	   Boc),	   1486,	   1439,	   1395,	   1369,	   1236,	   1161,	   765;	  HRMS	  
(ESI)	   m/z	   calcd	   for	   C14H24N2NaO6	   (M+Na)
+	   339.1527,	  
found	  339.1526	  (+0.2	  ppm	  error).	   	  
7-­‐Methyl-­‐1,1-­‐diphenyl-­‐hexahydro-­‐1H-­‐[1,3]oxazolo[3,4-­‐
a]pyrazin-­‐3-­‐one	   (9)	   and	   tert-­‐butyl	   2-­‐
(hydroxydiphenylmethyl)-­‐4-­‐methylpiperazine-­‐1-­‐
carboxylate	   (10).	  N-­‐Boc-­‐N’-­‐methyl	   piperazine	  4	   (200	  mg,	  
1.0	  mmol),	   s-­‐BuLi	   (1.3	  M	   solution	   in	   hexanes,	   1.0	  mL,	   1.3	  
mmol)	  and	  benzophenone	  (364	  mg,	  2.0	  mmol)	  in	  THF	  (1	  
mL)	   gave,	   after	   purification	   (SiO2,	   98:2	   to	   95:5	   CH2Cl2-­‐
MeOH),	  oxazolidinone	  9	   (263	  mg,	  83%)	  as	  a	  white	  solid,	  
RF	   (19:1	   CH2Cl2-­‐MeOH)	   0.4;	   mp	   96-­‐98	   °C;	  
1H	  NMR	   (400	  
MHz,	  CDCl3)	  δ	  7.52-­‐7.47	  (m,	  2H),	  7.37-­‐7.23	  (m,	  8H),	  4.50	  
(dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  3.83	  (ddd,	  J	  =	  13.0,	  3.5,	  1.0	  Hz,	  1H),	  
3.12	  (ddd,	  J	  =	  13.0,	  12.0,	  3.5	  Hz,	  1H),	  2.68-­‐2.64	  (m,	  1H),	  2.43	  
(ddd,	  J	  =	  12.0,	  3.5,	  1.0	  Hz,	  1H),	  2.18	  (s,	  3H),	  1.93	  (td,	  J	  =	  12.0,	  
3.5	  Hz,	  1H),	  1.43	  (t,	  J	  =	  11.0	  Hz,	  1H);	   13C	  NMR	  (100.6	  MHz,	  
CDCl3)	  δ	   158.8,	   142.2,	   138.6,	   128.5,	   128.3,	   128.2,	   127.8,	   125.8,	  
125.6,	   85.1,	   60.9,	   56.9,	   53.2,	   46.3,	   41.5;	   IR	   (CHCl3)	   2948,	  
2804,	   1751	   (C=O),	   1450,	   1409,	   1360,	   1301,	   1255,	   1138,	   1032,	  
988,	   757	   cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C19H21N2O2	  
(M+H)+	   309.1598,	   found	   309.1599	   (+0.1	   ppm	   error)	   and	  
alcohol	  10	  (45	  mg,	  12%)	  as	  a	  pale	  yellow	  oil,	  RF	  (9:1	  CH2Cl2-­‐
MeOH)	  0.5;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  (50:50	  mixture	  of	  
rotamers)	   δ	   7.70-­‐7.07	   (m,	   10H),	   5.23	   (br	   d,	   J	   =	   4.0	   Hz,	  
0.5H),	   4.90	   (br	   d,	   J	   =	   4.0	   Hz,	   0.5H),	   4.17-­‐4.11	   (m,	   0.5H),	  
3.86-­‐3.72	  (m,	  1.5H),	  2.97-­‐2.92	  (m,	  1H),	  2.87-­‐2.84	  (m,	  0.5H),	  
2.78-­‐2.76	  (m,	  0.5H),	  2.28	  (dd,	  J	  =	  12.0,	  4.0	  Hz,	  0.5H),	  2.24	  
(dd,	   J	   =	   12.0,	   4.0	   Hz,	   0.5H),	   2.17	   (s,	   1.5H),	   2.14	   (s,	   1.5H),	  
2.10-­‐1.98	   (m,	   1H),	   1.25	   (s,	   4.5H),	   1.21	   (s,	   4.5H);	   13C	   NMR	  
(100.6	  MHz,	   CDCl3)	   (mixture	   of	   rotamers)	   δ	   154.6,	   154.2,	  
147.7,	   147.2,	   145.0,	   144.7,	   128.3,	   128.1,	   127.5,	   127.3,	   126.7,	  
126.6,	   126.5	   	   126.3,	   126.1,	   126.0,	   83.5,	   83.4,	   79.8,	   79.7,	   56.6,	  
55.8,	  55.2,	  54.4,	  54.3,	  53.5,	  45.8,	  45.7,	  41.4,	  40.3,	  28.2,	  28.0;	  
IR	  (CHCl3)	  3680	  (OH),	  3019,	  2980,	  2855,	  2807,	  1681	  (C=O),	  
1461,	   1417,	   1367,	   1350,	   1304,	   1287,	   1215,	   1169,	   1146,	   1027,	   765	  
cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C23H31N2O3	   (M+H)
+	  
383.2329,	  found	  383.2317	  (+3.6	  ppm	  error).	  
tert-­‐Butyl	   N-­‐ethenyl-­‐N-­‐[2-­‐
(methylamino)ethyl]carbamate	   (5)	   and	   tert-­‐butyl	   N-­‐[2-­‐
(methylamino)ethyl]-­‐N-­‐[1-­‐
(trimethylsilyl)ethenyl]carbamate	   (11).	  s-­‐BuLi	   (1.85	  mL	  of	  
a	   1.3	  M	   solution	   in	  hexanes,	   2.4	  mmol)	  was	   added	  drop-­‐
wise	  to	  a	  stirred	  solution	  of	  N-­‐Boc-­‐N′-­‐methyl	  piperazine	  4	  
(200	  mg,	   1.0	  mmol)	   and	   TMEDA	   (360	   µL,	   2.4	  mmol)	   in	  
Et2O	   (7	  mL)	   at	   –78	   °C	   under	   Ar.	   The	   resulting	   solution	  
was	  warmed	  to	  –10	  °C	  and	  stirred	  for	  1	  h.	  The	  solution	  was	  
cooled	   to	   –78	   °C	   then	   Me3SiCl	   (305	   µL,	   2.4	   mmol)	   was	  
added	  dropwise.	  The	  reaction	  mixture	  was	  warmed	  to	  –60	  
 
°C,	   stirred	   for	   1	   h	   then	   allowed	   to	  warm	   to	   rt	   over	   16	   h.	  
Then,	   saturated	  NH4Cl(aq)	   (10	  mL)	   and	   20%	  NaOH(aq)	   (10	  
mL)	  were	   added	  and	   the	   two	   layers	  were	   separated.	  The	  
aqueous	   layer	  was	   extracted	  with	   Et2O	   (3	   ×	   10	  mL).	   The	  
combined	  organic	  layers	  were	  dried	  (MgSO4),	  filtered	  and	  
evaporated	   under	   reduced	   pressure	   to	   give	   the	   crude	  
products.	   Purification	   by	   flash	   column	   chromatography	  
(SiO2,	  9:1	  CH2Cl2-­‐MeOH)	  gave	  vinyl	  carbamate	  5	   (75	  mg,	  
37%)	  as	  a	  pale	  yellow	  oil	  and	  silane	  11	  (86	  mg,	  32%)	  as	  a	  
pale	   yellow	  oil,	  RF	   (9:1	  CH2Cl2-­‐MeOH)	  0.2;	  
1H	  NMR	   (400	  
MHz,	  CDCl3)	  δ	  5.38	  (br	  s,	  1H),	  5.13	  (br	  s,	  1H),	  3.59	  (t,	  J	  =	  7.0	  
Hz,	   2H),	   2.79	   (t,	   J	   =	   7.0	  Hz,	   2H),	   2.53	   (br	   s,	   1H),	   2.49	   (s,	  
3H),	  1.47	  (s,	  9H),	  0.15	  (s,	  9H);	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  
δ	   154.4,	  153.3,	  112.7	  (br),	  80.6,	  49.5,	  46.7,	  35.6,	  28.5,	  0.5;	  IR	  
(CHCl3)	  2972,	  1656	  (C=O),	  1432,	  1372,	  1346,	  1228,	  1197,	  1136,	  
831,	   742	   cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C13H29N2O2Si	  
(M+H)+	  273.1993,	  found	  273.2000	  (–1.9	  ppm	  error).	  
TMEDA	  mediated	   lithiation/trapping	   of	  N-­‐Boc-­‐N’-­‐
tert-­‐butyl	   piperazine	   12	   and	  N-­‐Boc-­‐N’-­‐cumyl	   pipera-­‐
zine	   16.	   s-­‐BuLi	   (1.3	   M	   solution	   in	   hexanes,	   1.3	   eq.)	   was	  
added	  dropwise	  to	  a	  stirred	  solution	  of	  N-­‐Boc	  piperazine	  
(0.5-­‐1.0	  mmol,	   1.0	  eq.)	  and	  TMEDA	  (1.3	  eq.)	   in	  Et2O	  (0.14	  
M)	  at	  –78	  °C	  under	  Ar.	  The	  resulting	  solution	  was	  stirred	  
at	  –78	  °C	  for	  1	  h.	  Then	  the	  electrophile	  (2.0	  eq.)	  was	  added	  
dropwise,	   as	   a	   solution	   in	   THF	   (1	  mL)	   if	   necessary.	   The	  
reaction	  mixture	  was	  stirred	  at	  –78	  °C	  for	  15	  min	  and	  then	  
allowed	   to	   warm	   to	   rt	   over	   30	   min.	   Then,	   saturated	  
NH4Cl(aq)	  (10	  mL),	  20%	  NaOH(aq)	  (10	  mL)	  and	  Et2O	  (10	  mL)	  
were	  added	  and	  the	  two	  layers	  were	  separated.	  The	  aque-­‐
ous	   layer	  was	  extracted	  with	  Et2O	  (3	  ×	  10	  mL).	  The	  com-­‐
bined	   organic	   layers	   were	   dried	   (MgSO4),	   filtered	   and	  
evaporated	   under	   reduced	   pressure	   to	   give	   the	   crude	  
product	  which	  was	  purified	  by	   flash	   column	  chromatog-­‐
raphy	  on	  silica	  gel.	  	  
tert-­‐Butyl	   4-­‐(2-­‐phenylpropan-­‐2-­‐yl)-­‐2-­‐
(trimethylsilyl)piperazine-­‐1-­‐carboxylate	   (18a).	   N-­‐Boc-­‐N’-­‐
cumyl	   piperazine	   16	   (152	   mg,	   0.5	   mmol),	   s-­‐BuLi	   (1.3	   M	  
solution	  in	  hexanes,	  0.5	  mL,	  0.65	  mmol),	  TMEDA	  (97	  µL,	  
0.65	   mmol)	   and	   Me3SiCl	   (127	   µL,	   1.0	   mmol)	   gave,	   after	  
purification	  (SiO2,	  9:1	  petrol-­‐Et2O),	  substituted	  piperazine	  
18a	  (184	  mg,	  98%)	  as	  a	  colourless	  oil;	  RF	  (9:1	  petrol-­‐Et2O)	  
0.3;	   1H	  NMR	   (400	  MHz,	   CDCl3)	   (60:40	   mixture	   of	   rota-­‐
mers)	  δ	  7.52-­‐7.47	  (m,	  2H),	  7.34-­‐7.28	  (m,	  2H),	  7.24-­‐7.18	  (m,	  
1H),	   3.95	   (br	   s,	   0.6H),	   3.72	   (br	   s,	   0.4H),	   3.63-­‐3.56	   (br	  m,	  
1H),	  2.95	  (dt,	  J	  =	  11.5,	  2.0	  Hz,	  1H),	  2.93	  (br	  s,	  0.4H),	  2.84	  (br	  
s,	  0.6H),	  2.45	  (br	  s,	  2H),	  2.03	  (td,	  J	  =	  11.5,	  3.0	  Hz,	  1H),	  1.43	  
(s,	   9H),	   1.35	   (s,	   6H),	   0.13	   (s,	   9H);	   13C	   NMR	   (100.6	   MHz,	  
CDCl3)	   (mixture	   of	   rotamers)	   δ	   154.5,	   154.4,	   148.4,	   127.9,	  
126.3,	  126.3,	  79.1,	  59.9,	  47.1,	  46.9,	  46.5,	  45.7,	  44.7,	  43.7,	  42.0,	  
28.4,	   26.7,	   20.4,	   –0.6;	   IR	   (CHCl3)	   2965,	   2931,	   1645	   (C=O),	  
1428,	   1399,	   1344,	   1277,	   1261,	   1228,	   1197,	   1154,	   1094,	  916,	  825,	  
749,	   691	   cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C21H37N2O2Si	  
(M+H)+	  377.2619,	  found	  377.2601	  (+4.3	  ppm	  error).	  
tert-­‐Butyl	   4-­‐(2-­‐phenylpropan-­‐2-­‐yl)-­‐2-­‐
(tributylstannyl)piperazine-­‐1-­‐carboxylate	  (18b).	  N-­‐Boc-­‐N’-­‐
cumyl	   piperazine	   16	   (152	   mg,	   0.5	   mmol),	   s-­‐BuLi	   (1.3	   M	  
solution	  in	  hexanes,	  0.5	  mL,	  0.65	  mmol),	  TMEDA	  (97	  µL,	  
0.65	   mmol)	   and	   Bu3SnCl	   (271	   µL,	   1.0	   mmol)	   gave,	   after	  
purification	   (SiO2,	   19:1	   petrol-­‐Et2O),	   substituted	   pipera-­‐
zine	  18b	  (260	  mg,	  81%)	  as	  a	  colourless	  oil;	  RF	  (19:1	  petrol-­‐
EtOAc)	  0.3;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  (50:50	  mixture	  of	  
rotamers)	   δ	   7.49	   (d,	   J	   =	   7.5	  Hz,	   2H),	   7.29	   (t,	   J	   =	   7.5	  Hz,	  
2H),	   7.23-­‐7.16	   (m,	   1H),	  4.21-­‐4.12	   (m,	  0.5H),	   3.97	   (br	  d,	   J	   =	  
12.0	   Hz,	   0.5H),	   3.60-­‐3.25	   (m,	   1.5H),	   2.86-­‐2.52	   (m,	   2.5H),	  
2.31	  (br	  s,	  1H),	  2.06-­‐1.84	  (m,	  1H),	  1.55-­‐1.37	  (m,	  15H),	  1.33-­‐1.22	  
(m,	  12H),	  0.95-­‐0.83	  (m,	  15H);	  13C	  NMR	  (100.6	  MHz,	  CDCl3)	  
(mixture	   of	   rotamers)	   δ	   154.6,	   153.9,	   148.3,	   148.2,	   128.0,	  
126.3,	   79.3,	   79.0,	   60.0,	   50.2,	   46.9,	   45.9,	   45.6,	   43.0,	   29.2,	  
28.4,	   27.9,	   27.8,	   27.6,	   27.3,	   26.8,	   25.7,	   22.1,	   20.7,	   13.7,	   11.1,	  
10.4;	   IR	   (CHCl3)	   2971,	   2913,	   2881,	   2827,	   1645	   (C=O),	   1432,	  
1397,	   1344,	   1280,	   1197,	   1152,	   1090,	   1002,	  947,	  908,	  849,	  743,	  
691,	   658	   cm–1;	   HRMS	   (ESI)	  m/z	   calcd	   for	   C30H55N2O2Sn	  
(M+H)+	   595.3285,	   found	  595.3261	   (+3.6	  ppm	  error).	  Spec-­‐
troscopic	  data	  consistent	  with	  those	  reported	  in	  the	  liter-­‐
ature.13	  
tert-­‐Butyl	   2-­‐methyl-­‐4-­‐(2-­‐phenylpropan-­‐2-­‐yl)piperazine-­‐
1-­‐carboxylate	   (18c).	   N-­‐Boc-­‐N’-­‐cumyl	   piperazine	   16	   (152	  
mg,	  0.5	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  0.5	  mL,	  
0.65	  mmol),	  TMEDA	  (97	  µL,	  0.65	  mmol)	  and	  MeI	  (62	  µL,	  
1.0	  mmol)	  gave,	  after	  purification	  (SiO2,	  8:2	  petrol-­‐Et2O),	  
substituted	   piperazine	   18c	   (152	  mg,	   95%)	   as	   a	   colourless	  
oil;	  RF	  (8:2	  petrol-­‐Et2O)	  0.3;	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  
7.54-­‐7.51	  (m,	  2H),	  7.33-­‐7.27	  (m,	  2H),	  7.23-­‐7.18	  (m,	  1H),	  4.12	  
(br	  s,	  1H),	  3.75	  (br	  d,	  J	  =	  13.0	  Hz,	  1H),	  3.04	  (td,	  J	  =	  12.5,	  3.5	  
Hz,	   1H),	   2.76-­‐2.67	   (m,	   1H),	   2.52	   (dt,	   J	   =	   11.0,	   2.0	  Hz,	   1H),	  
2.31	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  2.14	  (td,	  J	  =	  12.5,	  3.5	  Hz,	  1H),	  
1.44	   (s,	   9H),	   1.33	   (s,	   3H),	   1.30	   (s,	   3H),	   1.22	   (d,	   J	   =	   7.0	  Hz,	  
3H);	   13C	   NMR	   (100.6	   MHz,	   CDCl3)	   δ	   154.9,	   149.2,	   128.0,	  
126.3,	   126.2,	   79.3,	   59.4,	   50.8,	   47.6,	   46.5,	   39.9,	   28.5,	   24.3,	  
23.6,	   15.8;	   IR	   (CHCl3)	   2931,	   1652	   (C=O),	   1427,	   1393,	   1345,	  
1300,	  1263,	  1214,	  1152,	  1093,	  1005,	  691	  cm–1;	  HRMS	  (ESI)	  m/z	  
calcd	   for	   C19H31N2O2	   (M+H)
+	   319.2380,	   found	   319.2369	  
(+3.5	  ppm	  error).	  
tert-­‐Butyl	   4-­‐(2-­‐phenylpropan-­‐2-­‐yl)-­‐2-­‐(prop-­‐2-­‐en-­‐1-­‐
yl)piperazine-­‐1-­‐carboxylate	  (18d).	  s-­‐BuLi	  (1.3	  M	  solution	  in	  
hexanes,	   0.5	   mL,	   0.65	   mmol)	   was	   added	   dropwise	   to	   a	  
stirred	  solution	  of	  N-­‐Boc-­‐N’-­‐cumyl	  piperazine	  16	  (152	  mg,	  
0.5	  mmol)	  and	  (97	  µL,	  0.65	  mmol)	  in	  Et2O	  (4	  mL)	  at	  –78	  
°C	  under	  Ar.	  The	  resulting	  solution	  was	  stirred	  at	  –78	  °C	  
for	   1	   h.	   Then,	   a	   solution	   of	   CuCN.2LiCl	   (0.25	  mmol,	   0.5	  
eq.)	   in	  THF	   (0.5	  mL)	  was	   added	  dropwise.	  The	   resulting	  
solution	  was	  stirred	  at	  –78	  °C	  for	  1	  h.	  Then,	  allyl	  bromide	  
(87	  µL,	  1.0	  mmol)	  was	  added	  dropwise.	  The	  reaction	  mix-­‐
ture	  was	  stirred	  at	  –78	  °C	  for	  15	  min	  and	  then	  allowed	  to	  
warm	  to	  rt	  over	  30	  min.	  Then,	   saturated	  NaHCO3(aq)	  was	  
added	   and	   the	   two	   layers	   were	   separated.	   The	   aqueous	  
layer	  was	  extracted	  with	  Et2O	  (3	  ×	  10	  mL).	  The	  combined	  
organic	  layers	  were	  dried	  (MgSO4)	  and	  evaporated	  under	  
reduced	   pressure	   to	   give	   the	   crude	   product.	   Purification	  
by	   flash	   column	   chromatography	   (SiO2,	   8:2	   petrol-­‐Et2O)	  
gave	   substituted	   piperazine	   18d	   (138	  mg,	   80%)	   as	   a	   col-­‐
ourless	   oil,	  RF	   (8:2	   petrol-­‐Et2O)	   0.3;	  
1H	  NMR	   (400	  MHz,	  
CDCl3)	   δ	   7.55-­‐7.48	   (m,	   2H),	   7.34-­‐7.28	   (m,	   2H),	   7.24-­‐7.18	  
(m,	  1H),	  5.73-­‐5.63	  (m,	  1H),	  5.09-­‐5.02	  (m,	  1H),	  4.99-­‐4.94	  (m,	  
1H),	  4.01	  (br	  s,	  1H),	  3.80	  (br	  s,	  1H),	  2.98	  (t,	  J	  =	  11.5	  Hz,	  1H),	  
2.67	  (br	  s,	  2H),	  2.57-­‐	  2.37	  (m,	  2H),	  2.26	  (dd,	  J	  =	  11.5,	  3.5	  Hz,	  
1H),	  2.21-­‐2.08	  (m,	  1H),	  1.43	  (s,	  9H),	  1.33	  (s,	  3H),	  1.30	  (s,	  3H);	  
13C	   NMR	   (100.6	  MHz,	   CDCl3)	   δ	   154.8,	   148.9,	   125.7,	   128.0,	  
 
126.3,	  126.0,	  116.8,	  79.3,	  59.4,	  52.0	  (br),	  48.0,	  46.4,	  39.6	  (br),	  
34.5,	   28.4,	   24.5,	   23.2;	   IR	   (CHCl3)	   2972,	   2930,	   2776,	   1658	  
(C=O),	  1397,	  1344,	  1305,	  1197,	  1153,	  1092,	  972,	  950,	  907,	  761,	  
732,	   691,	   658	   cm–1;	  HRMS	   (ESI)	  m/z	   calcd	   for	  C21H33N2O2	  
(M+H)+	  345.2537,	  found	  345.2526	  (+3.1	  ppm	  error).	  
1-­‐tert-­‐Butyl	   2-­‐methyl	   4-­‐(2-­‐phenylpropan-­‐2-­‐
yl)piperazine-­‐1,2-­‐dicarboxylate	   (18e).	   N-­‐Boc-­‐N’-­‐cumyl	  
piperazine	  16	  (152	  mg,	  0.5	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  
hexanes,	  0.5	  mL,	  0.65	  mmol),	  TMEDA	  (97	  µL,	  0.65	  mmol)	  
and	  MeOCOCl	   (77	  µL,	   1.0	  mmol)	   gave,	   after	  purification	  
(SiO2,	   97:3-­‐8:2	   CH2Cl2-­‐Et2O),	   substituted	   piperazine	   18e	  
(119	  mg,	   66%)	   as	   a	   pale	   yellow	   oil;	  RF	   (19:1	   CH2Cl2-­‐Et2O)	  
0.2;	   1H	   NMR	   (400	   MHz,	   CDCl3)	   (55:45	   mixture	   of	   rota-­‐
mers)	  δ	  7.42–7.37	  (m,	  2H),	  7.31–7.25	  (m,	  2H),	  7.23–7.17	  (m,	  
1H),	  4.66	  (br	  s,	  0.55H),	  4.50	  (br	  s,	  0.45H),	  3.80	  (d,	  J	  =	  11.0	  
Hz,	   0.55H),	   3.72	   (s,	   1.35H),	   3.70	   (s,	   1.65H),	   3.72-­‐3.69	   (m,	  
0.45H),	   3.35–3.19	   (m,	   1.55H),	   3.13	   (td,	   J	   =	   12.0,	   3.0	   Hz,	  
0.45H),	   2.74	   (d,	   J	   =	   10.5	  Hz,	   0.45H),	   2.67	   (d,	   J	   =	   10.5	  Hz,	  
0.55H),	  2.37	  (dd,	  J	  =	  11.5,	  3.5	  Hz,	  1HH),	  2.18	  (td,	  J	  =	  11.5,	  3.5	  
Hz,	   1H),	   1.46	   (s,	   5H),	   1.41	   (s,	   4H),	   1.31	   (s,	   6H);	   13C	   NMR	  
(100.6	   MHz,	   CDCl3)	   (mixture	   of	   rotamers)	   δ	   171.6,	   171.4,	  
156.0,	  155.4,	  148.4,	  148.3,	  127.9,	  126.3,	  125.9,	  80.1,	  59.2,	  56.0,	  
54.9,	  51.8,	  47.8,	  45.7,	  42.7,	  41.7,	  28.3,	  28.2,	  24.0,	  23.9,	  23.7;	  
IR	   (CHCl3)	   2972,	   2933,	   1718	   (C=O,	   CO2Me),	   1662	   (C=O,	  
Boc),	  1469,	  1452,	  1391,	  1369,	  1346,	  1331,	  1310,	  1284,	  1195,	  1155,	  
1101,	   1016,	   951,	   736,	   692	   cm–1;	   HRMS	   (ESI)	  m/z	   calcd	   for	  
C20H31N2O4	   (M+H)
+	   363.2278,	   found	   363.2277	   (0.0	   ppm	  
error).	  Spectroscopic	  data	  consistent	  with	  those	  reported	  
in	  the	  literature.13	  
1-­‐tert-­‐Butyl	   2-­‐methyl	   4-­‐tert-­‐butylpiperazine-­‐1,2-­‐
dicarboxylate	  (17a).	  N-­‐Boc-­‐N’-­‐tert-­‐butyl	  piperazine	  12	  (242	  
mg,	  1.0	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  1.0	  mL,	  
1.3	  mmol),	  TMEDA	  (195	  µL,	  1.3	  mmol)	  and	  MeOCOCl	  (155	  
µL,	   2.0	   mmol)	   gave,	   after	   purification	   (SiO2,	   7:3	   petrol-­‐
EtOAc),	  substituted	  piperazine	  17a	  (135	  mg,	  45%)	  as	  a	  pale	  
yellow	  oil;	  RF	  (7:3	  petrol-­‐EtOAc)	  0.4;	   	  
1H	  NMR	  (400	  MHz,	  
CDCl3)	   (50:50	   mixture	   of	   rotamers)	   δ	   4.70	   (br	   s,	   0.5H),	  
4.53	   (br	   s,	   0.5H),	   3.83	   (br	   d,	   J	   =	   12.5	  Hz,	   0.5H),	   3.75-­‐3.73	  
(m,	   0.5H),	   3.73	   (s,	   1.5H),	   3.72	   (s,	   1.5H),	   3.52-­‐3.45	   (m,	   1H),	  
3.13	   (td,	   J	   =	   12.5,	   3.5	  Hz,	   0.5H),	   3.03	   (td,	   J	   =	   12.5,	   3.5	  Hz,	  
0.5H),	  2.92	  (br	  d,	  J	  =	  11.0	  Hz,	  0.5H),	  2.84	  (br	  d,	  J	  =	  11.0	  Hz,	  
0.5H),	  2.28-­‐2.23	  (m,	  1H),	  2.11	  (td,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  1.46	  
(s,	  4.5H),	  1.42	  (s,	  4.5H),	  0.96	  (s,	  9H);	  13C	  NMR	  (100.6	  MHz,	  
CDCl3)	   (mixture	   of	   rotamers)	   δ	   171.6,	   171.3,	   155.8,	   155.4,	  
80.0,	  56.3,	  55.0,	  53.3,	  51.9,	  47.6,	  45.2,	  42.9,	  42.0,	  28.3,	  25.8;	  
IR	   (CHCl3)	   2976,	   1745	   (C=O,	   CO2Me),	   1689	   (C=O,	   Boc),	  
1455,	  1393,	  1367,	  1304,	  1253,	  1170,	  1119,	  1041,	  965,	  865,	  761	  cm–
1;	  HRMS	  (ESI)	  m/z	   calcd	   for	  C15H29N2O4	   (M+H)
+	   301.2122,	  
found	   301.2122	   (0.0	   ppm	   error).	   Spectroscopic	   data	   con-­‐
sistent	  with	  those	  reported	  in	  the	  literature.13	  
7-­‐(2-­‐Phenylpropan-­‐2-­‐yl)-­‐hexahydro-­‐1H-­‐[1,3]oxazolo[3,4-­‐
a]pyrazin-­‐3-­‐one	  (18f)	  and	  tert-­‐butyl	  2-­‐(hydroxymethyl)-­‐4-­‐
(2-­‐phenylpropan-­‐2-­‐yl)piperazine-­‐1-­‐carboxylate	   (18g).	   N-­‐
Boc-­‐N’-­‐cumyl	   piperazine	   16	   (152	   mg,	   0.5	   mmol),	   s-­‐BuLi	  
(1.3	  M	  solution	   in	  hexanes,	  0.5	  mL,	  0.65	  mmol),	  TMEDA	  
(97	   µL,	   0.65	   mmol)	   and	   paraformaldehyde	   (30	   mg,	   1.0	  
mmol)	  in	  Et2O	  (1	  mL)	  gave,	  after	  purification	  (SiO2,	  7:3-­‐1:1	  
petrol-­‐EtOAc),	   oxazolidinone	   18f	   (34	  mg,	   26%)	   as	   a	   pale	  
yellow	  oil,	  RF	   (7:3	   petrol-­‐EtOAc)	  0.1;	  
1H	  NMR	   (400	  MHz,	  
CDCl3)	   δ	   7.53-­‐7.47	   (m,	   2H),	   7.35-­‐7.29	   (m,	   2H),	   7.26-­‐7.20	  
(m,	  1H),	  4.32	  (t,	  J	  =	  8.0	  Hz,	  1H),	  3.88-­‐3.72	  (m,	  3H),	  3.05	  (td,	  
J	  =	  12.0,	  3.5	  Hz,	  1H),	  2.85-­‐2.74	  (m,	  2H),	  2.21	  (td,	  J	  =	  12.0,	  3.5	  
Hz,	   1H),	   2.04	   (t,	   J	   =	   11.0	   Hz,	   1H),	   1.34	   (s,	   6H);	   13C	   NMR	  
(100.6	  MHz,	  CDCl3)	  δ	   157.0,	   148.3,	   128.2,	   126.5,	   125.9,	  65.5,	  
60.2,	  54.0,	  51.3,	  45.4,	  42.0,	  25.2,	  23.1;	  IR	  (CHCl3)	  2973,	  1720	  
(C=O),	   1496,	   1545,	   1404,	   1194,	   1045,	  914,	   771,	   725,	  659,	  617	  
cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	   C15H21N2O2	   (M+H)
+	  
261.1598,	  found	  261.1587	  (+3.9	  ppm	  error)	  and	  substituted	  
piperazine	   18g	   (96	  mg,	   57%)	   as	   a	   pale	   yellow	  oil,	  RF	   (7:3	  
petrol-­‐EtOAc)	  0.2;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.43	  (d,	  J	  
=	   7.5	  Hz,	   2H),	   7.32	   (t,	   J	   =	   7.5	  Hz,	   2H),	   7.25-­‐7.20	   (m,	   1H),	  
4.19-­‐3.57	  (m,	  5H),	  3.26	  (br	  s,	  1H),	  2.94	  (d,	  J	  =	  11.0	  Hz,	  1H),	  
2.72	   (br	   s,	   1H),	  2.41	   (dd,	   J	  =	   11.5,	  4.0	  Hz,	   1H),	  2.19	   (td,	   J	  =	  
11.5,	  3.0	  Hz,	  1H),	  1.44	  (s,	  9H),	  1.38	  (s,	  6H);	   13C	  NMR	  (100.6	  
MHz,	  CDCl3)	  δ	   155.0,	   147.4,	   128.3,	   126.7,	   125.9,	   79.8,	   65.4,	  
59.9,	  52.0,	  48.1,	  46.2,	  42.1,	  28.5,	  24.2,	  22.7;	  IR	  (CHCl3)	  2972,	  
2933,	   1655	   (C=O),	   1392,	   1370,	   1345,	   1290,	   1196,	   1152,	   1100,	  
995,	   895,	   767,	   747,	   728,	   692,	   658	   cm–1;	   HRMS	   (ESI)	  m/z	  
calcd	  for	  C19H31N2O3	  (M+H)




cyclohexane]-­‐3-­‐one	   (18h).	  N-­‐Boc-­‐N’-­‐cumyl	   piperazine	   16	  
(152	  mg,	  0.5	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  0.5	  
mL,	  0.65	  mmol),	  TMEDA	  (97	  µL,	  0.65	  mmol)	   and	  cyclo-­‐
hexanone	   (104	   mg,	   1.0	   mmol)	   gave,	   after	   purification	  
(SiO2,	   9:1-­‐7:3	   petrol-­‐EtOAc),	   oxazolidinone	   18h	   (95	   mg,	  
58%)	   as	   a	   pale	   yellow	   oil,	   RF	   (8:2	   petrol-­‐EtOAc)	   0.2;	  
1H	  
NMR	  (400	  MHz,	  CDCl3)	  δ	  7.49	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.31	  (t,	  J	  
=	  7.5	  Hz,	  2H),	  7.22	  (t,	  J	  =	  7.5	  Hz,	  1H),	  3.73	  (dd,	  J	  =	  13.0,	  2.0	  
Hz,	  1H),	  3.31	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  2.97	  (td,	  J	  =	  12.0,	  3.5	  
Hz,	  1H),	  2.76-­‐2.67	  (m,	  2H),	  2.19-­‐2.06	  (m,	  2H),	  1.91-­‐1.40	  (m,	  
10H),	   1.33	   (s,	   6H);	   13C	   NMR	   (100.6	  MHz,	   CDCl3)	   δ	   156.5,	  
148.5,	   128.2,	   126.4,	   125.8,	   80.8,	   62.7,	   60.3,	   46.7,	   45.4,	   41.9,	  
36.8,	  30.7,	  25.0,	  24.4,	  24.1,	  22.0,	  21.9;	  IR	  (CHCl3)	  2972,	  2930,	  
2895,	   1708	   (C=O),	   1497,	   1425,	   1404,	   1342,	   1263,	   1199,	   1162,	  
913,	   771,	   726,	   691,	   658	   cm–1;	   HRMS	   (ESI)	  m/z	   calcd	   for	  
C20H29N2O2	   (M+H)
+	   329.2224,	   found	   329.2207	   (+4.6	   ppm	  
error).	  
1,1-­‐Diphenyl-­‐7-­‐(2-­‐phenylpropan-­‐2-­‐yl)-­‐hexahydro-­‐1H-­‐
[1,3]oxazolo[3,4-­‐a]pyrazin-­‐3-­‐one	   (18i)	   and	   tert-­‐butyl	   2-­‐
(hydroxydiphenylmethyl)-­‐4-­‐(2-­‐phenylpropan-­‐2-­‐
yl)piperazine-­‐1-­‐carboxylate	   (18j).	  N-­‐Boc-­‐N’-­‐cumyl	   pipera-­‐
zine	  16	  (152	  mg,	  0.5	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hex-­‐
anes,	   0.5	   mL,	   0.65	   mmol),	   TMEDA	   (97	   µL,	   0.65	   mmol)	  
and	  benzophenone	  (182	  mg,	   1.0	  mmol)	  gave,	  after	  purifi-­‐
cation	  (SiO2,	  9:1-­‐8:2	  petrol-­‐EtOAc),	  oxazolidinone	  18i	  (152	  
mg,	   74%)	   as	   a	  white	   solid,	  RF	   (7:3	   petrol-­‐EtOAc)	   0.1;	  mp	  
122-­‐124	   °C;	   1H	   NMR	   (400	   MHz,	   CDCl3)	   δ	   7.49–7.43	   (m,	  
4H),	  7.39–7.19	  (m,	  11H),	  4.42	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  3.83–
3.72	  (m,	   1H),	  3.04	  (td,	   J	  =	   12.0,	  4.0	  Hz,	   1H),	  2.69–2.63	  (m,	  
1H),	  2.56	  (ddd,	  J	  =	  11.5,	  3.5,	  2.0	  Hz,	  1H),	  2.09	  (td,	  J	  =	  11.5,	  3.5	  
Hz,	  1H),	  1.55	  (t,	  J	  =	  11.0	  Hz,	  1H),	  1.24	  (s,	  3H),	  1.18	  (s,	  3H);	  13C	  
NMR	  (100.6	  MHz,	  CDCl3)	  δ	  156.2,	  148.3,	  142.5,	  138.9,	  128.5,	  
128.3,	  128.2,	  128.1,	  127.8,	  126.5,	  125.9,	  125.8,	  125.7,	  88.3,	  62.4,	  
60.2,	  49.3,	  45.3,	  42.5,	  25.0,	  23.3;	  	  IR	  (CHCl3)	  2963,	  2931,	  1723	  
(C=O),	   1470,	   1426,	   1390,	   1342,	   1282,	   1241,	   1159,	   1100,	   1059,	  
1016,	   971,	   895,	   690	   cm–1;	   HRMS	   (ESI)	   m/z	   calcd	   for	  
 
C27H29N2O2	   (M+H)
+	   413.2224,	   found	   413.2216	   (+2.6	   ppm	  
error)	   and	   substituted	   piperazine	   18j,	   (55	  mg,	   23%)	   as	   a	  
white	   solid,	   RF	   (7:3	   petrol-­‐EtOAc)	   0.2;	   mp	   54-­‐56	   °C;	  
1H	  
NMR	   (400	   MHz,	   CDCl3)	   (50:50	   mixture	   of	   rotamers)	   δ	  
8.25	  (s,	  0.5H),	  8.10	  (s,	  0.5H),	  7.70	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.62	  
(t,	   J	  =	  7.5	  Hz,	  2H),	  7.46	   (d,	   J	  =	  7.5	  Hz,	   1H),	  7.42-­‐7.07	   (m,	  
10H),	  5.16	  (d,	  J	  =	  3.0	  Hz,	  0.5H),	  4.84	  (d,	  J	  =	  3.0	  Hz,	  0.5H),	  
4.09	  (dd,	  J	  =	  13.5,	  3.0	  Hz,	  0.5H),	  3.82-­‐3.62	  (m,	  1.5H),	  3.27-­‐
3.16	  (m,	  1H),	  2.69	  (d,	  J	  =	  11.0	  Hz,	  0.5H),	  2.61	  (d,	  J	  =	  11.0	  Hz,	  
0.5H),	  2.46	  (dd,	  J	  =	  11.5,	  4.0	  Hz,	  0.5H),	  2.41	  (dd,	  J	  =	  11.5,	  4.0	  
Hz,	   0.5H),	   2.25-­‐2.09	   (m,	   1H),	   1.32	   (s,	   1.5H),	   1.29	   (s,	   1.5H),	  
1.24	  (s,	  1.5H),	  1.22	  (s,	  4.5H),	  1.16	  (s,	  1.5H),	  1.15	  (s,	  4.5H);	  13C	  
NMR	   (100.6	  MHz,	   CDCl3)	   (mixture	   of	   rotamers)	   δ	   154.5,	  
154.2,	   147.1,	   146.5,	   145.7,	   145.5,	   145.0,	   144.7,	   128.4,	   128.1,	  
128.0,	   127.6,	   127.5,	   127.3,	   126.9,	   126.9,	   126.8,	   126.7,	   126.5,	  
126.4,	  126.4,	  126.2,	  126.2,	  126.0,	  126.0,	  83.9,	  83.8,	  79.6,	  60.3,	  
60.3,	  55.6,	  54.0,	  48.5,	  47.5,	  46.8,	  46.7,	  42.2,	  41.2,	  28.1,	  27.9,	  
26.4,	   26.3,	   19.7,	   19.6;	   IR	   (CHCl3)	   2961,	   2934,	   1655	   (C=O),	  
1427,	   1395,	   1345,	   1326,	   1284,	   1232,	   1151,	   1096,	   1001,	  957,	  690,	  
628	   cm–1;	  HRMS	   (ESI)	  m/z	   calcd	   for	   C30H39N2O3	   (M+H)
+	  
487.2955,	  found	  487.2944	  (+2.4	  ppm	  error).	  Spectroscopic	  
data	   of	   18i	   consistent	   with	   those	   reported	   in	   the	   litera-­‐
ture.13	  
7-­‐tert-­‐Butyl-­‐1,1-­‐diphenyl-­‐hexahydro-­‐1H-­‐[1,3]oxazolo[3,4-­‐
a]pyrazin-­‐3-­‐one	   (17b).	   N-­‐Boc-­‐N’-­‐tert-­‐butyl	   piperazine	   12	  
(242	  mg,	  1.0	  mmol),	  s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  1.0	  
mL,	  1.3	  mmol),	  TMEDA	  (195	  µL,	  1.3	  mmol)	  and	  benzophe-­‐
none	  (364	  mg,	  2.0	  mmol)	  in	  Et2O	  (1	  mL)	  gave,	  after	  purifi-­‐
cation	  (SiO2,	  99:1-­‐98:2	  CH2Cl2-­‐MeOH),	  oxazolidinone	  17b	  
(200	  mg,	   57%),	   as	   a	  white	   solid,	  RF	   (99:1	  CH2Cl2-­‐MeOH)	  
0.2;	  mp	  193-­‐195	  °C;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.53-­‐7.50	  
(m,	  2H),	  7.39-­‐7.24	  (m,	  8H),	  4.43	  (dd,	  J	  =	  11.0,	  3.5	  Hz,	  1H),	  
3.85	  (ddd,	  J	  =	  13.0,	  3.5,	  1.0	  Hz,	  1H),	  3.08	  (ddd,	  J	  =	  13.0,	  12.0,	  
3.5	  Hz,	   1H),	  2.92-­‐2.88	  (m,	   1H),	  2.62	   (ddd,	   J	  =	   12.0,	  3.5,	   1.0	  
Hz,	   1H),	  2.06	  (td,	   J	  =	   12.0,	  3.5	  Hz,	   1H),	   1.51	   (t,	   J	  =	   11.0	  Hz,	  
1H),	   0.93	   (s,	   9H);	   13C	   NMR	   (100.6	   MHz,	   CDCl3)	   δ	   156.1,	  
142.4,	  138.8,	  128.5,	  128.4,	  128.2,	  127.8,	  126.0,	  125.7,	  85.4,	  61.9,	  
54.3,	   48.8,	   44.8,	   42.6,	   26.0;	   IR	   (CHCl3)	   2975,	   1750	   (C=O),	  
1449,	   1363,	   1302,	   1255,	   1203,	   1036,	   984	   cm–1;	   HRMS	   (ESI)	  
m/z	  calcd	  for	  C22H26N2O2	  (M+H)
+	  351.2067,	  found	  351.2062	  
(+0.7	   ppm	   error).	   Spectroscopic	   data	   consistent	   with	  
those	  reported	  in	  the	  literature.17	  
tert-­‐Butyl	   4-­‐benzyl-­‐2-­‐phenylpiperazine-­‐1-­‐carboxylate	  
(19)	   and	   tert-­‐butyl	   4-­‐benzyl-­‐3-­‐phenylpiperazine-­‐1-­‐
carboxylate	   (20).	   s-­‐BuLi	   (1.3	   M	   solution	   in	   hexanes,	   1.0	  
mL,	  1.3	  mmol)	  was	  added	  dropwise	  to	  a	  stirred	  solution	  of	  
N-­‐Boc-­‐N′-­‐benzyl	  piperazine	  1	   (276	  mg,	   1.0	  mmol)	   in	  THF	  
(7	   mL)	   at	   –78	   °C	   under	   Ar.	   The	   resulting	   solution	   was	  
stirred	   at	   –78	   °C	   for	   1	   h.	   Then,	   ZnCl2	   (1.0	  M	   solution	   in	  
Et2O,	  0.6	  mL,	  0.6	  mmol)	  was	  added	  and	  the	  resulting	  so-­‐
lution	  was	  stirred	  at	  –78	  °C	  for	  30	  min.	  The	  solution	  was	  
allowed	  to	  warm	  to	  rt	  and	  stirred	  at	  rt	   for	  30	  min.	  Then,	  
bromobenzene	  (140	  μL,	  1.3	  mmol)	  was	  added,	  followed	  by	  
the	   addition	   of	   Pd(OAc)2	   (11	   mg,	   0.05	   mmol)	   and	  
tBu3PHBF4	  (18	  mg,	  0.06	  mmol).	  The	  mixture	  was	  stirred	  at	  
rt	  for	  16	  h.	  Then,	  35%	  NH4OH(aq)	  (0.2	  mL)	  was	  added	  and	  
the	   solution	   stirred	   at	   rt	   for	   30	  min.	  The	   solids	  were	   re-­‐
moved	  by	  filtration	  through	  Celite®	  and	  washed	  with	  Et2O	  
(20	  mL).	  The	  filtrate	  was	  washed	  with	  H2O	  (20	  mL),	  dried	  
(MgSO4),	  filtered	  and	  evaporated	  under	  reduced	  pressure	  
to	   give	   the	   crude	   product.	   Purification	   by	   flash	   column	  
chromatography	   (SiO2,	   19:1	   petrol-­‐EtOAc)	   	   gave	   a	   33:67	  
mixture	  of	  substituted	  piperazines	  19	  and	  20	  (by	   1H	  NMR	  
spectroscopy)	   (147	   mg,	   42%)	   as	   a	   colourless	   oil,	   RF	   (9:1	  
petrol-­‐EtOAc)	  0.3;	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.51-­‐7.47	  
(m,	   1.34H),	   7.31-­‐7.19	   (m,	   8.66H),	   5.23	   (br	   s,	   0.33H),	   4.10-­‐
3.89	  (m,	  1.67),	  3.79	  (d,	  J	  =	  13.5	  Hz,	  0.67H),	  3.57	  (d,	  J	  =	  13.0	  
Hz,	  0.33H),	  3.45	  (d,	  J	  =	  13.0	  Hz,	  0.33H),	  3.30-­‐3.27	  (m,	  1H),	  
3.03	   (td,	   J	   =	   12.5,	   3.5	   Hz,	   0.33H),	   3.02-­‐2.76	   (m,	   3H),	   2.41	  
(dd,	   J	   =	   12.0,	   4.0	   Hz,	   0.33H),	   2.16	   (td,	   J	   =	   12.0,	   3.5	   Hz,	  
0.33H),	  2.07	  (td,	  J	  =	  12.0,	  3.0	  Hz,	  0.67H),	  1.47	  (s,	  3H),	  1.45	  
(s,	   6H);	   HRMS	   (ESI)	  m/z	   calcd	   for	   C22H29N2O2	   (M+H)
+	  
353.2224,	   found	   353.2224	   (0.0	   ppm	   error).	   Spectroscopic	  
data	   of	   20	   consistent	   with	   those	   reported	   in	   the	   litera-­‐
ture.25	  
s-­‐BuLi	  (1.3	  M	  solution	  in	  hexanes,	  1.0	  mL,	  1.3	  mmol)	  was	  
added	   dropwise	   to	   a	   stirred	   solution	   of	  N-­‐Boc-­‐N′-­‐benzyl	  
piperazine	  1	  (276	  mg,	  1.0	  mmol)	  in	  THF	  (7	  mL)	  at	  –78	  °C	  
under	  Ar.	  The	  resulting	  solution	  was	  stirred	  at	  –78	  °C	  for	  1	  
h.	  Then,	  ZnCl2	  (1.0	  M	  solution	  in	  Et2O,	  0.6	  mL,	  0.6	  mmol)	  
was	  added	  and	  the	  resulting	  solution	  was	  stirred	  at	  –78	  °C	  
for	   30	  min.	  The	   solution	  was	   allowed	   to	  warm	   to	   rt	   and	  
stirred	  at	  rt	   for	  30	  min.	  Then,	  bromobenzene	  (140	  μL,	   1.3	  
mmol)	  was	  added,	  followed	  by	  the	  addition	  of	  PEPPSI-­‐iPr	  
(34	  mg,	  0.05	  mmol).	  The	  mixture	  was	  stirred	  at	  rt	  for	  16	  h.	  
Then,	   35%	  NH4OH(aq)	   (0.2	  mL)	  was	   added	   and	   the	   solu-­‐
tion	  stirred	  at	  rt	   for	  30	  min.	  The	  solids	  were	  removed	  by	  
filtration	  through	  Celite®	  and	  washed	  with	  Et2O	  (20	  mL).	  
The	   filtrate	   was	   washed	   with	   H2O	   (20	   mL),	   dried	  
(MgSO4),	  filtered	  and	  evaporated	  under	  reduced	  pressure	  
to	   give	   the	   crude	   product.	   Purification	   by	   flash	   column	  
chromatography	   (SiO2,	   19:1	   petrol-­‐EtOAc)	   gave	   a	   5:95	  
mixture	  of	  substituted	  piperazines	  19	  and	  20	  (by	   1H	  NMR	  
spectroscopy)	  (54	  mg,	  38%)	  as	  a	  colourless	  oil.	  
tert-­‐Butyl	   2-­‐phenyl-­‐4-­‐(2-­‐phenylpropan-­‐2-­‐yl)piperazine-­‐
1-­‐carboxylate	   (21)	   and	   tert-­‐butyl	   N-­‐ethenyl-­‐N-­‐{2-­‐[(2-­‐
phenylpropan-­‐2-­‐yl)amino]ethyl}carbamate	   (22).	   s-­‐BuLi	  
(1.3	  M	  solution	  in	  hexanes,	  0.5	  mL,	  0.65	  mmol)	  was	  added	  
dropwise	   to	  a	   stirred	   solution	  of	  N-­‐Boc-­‐N′-­‐cumyl	  pipera-­‐
zine	  16	  (152	  mg,	  0.5	  mmol)	  in	  THF	  (4	  mL)	  at	  –78	  °C	  under	  
Ar.	   The	   resulting	   solution	  was	   stirred	   at	   –78	   °C	   for	   2	   h.	  
Then,	   ZnCl2	   (1.0	  M	   solution	   in	   Et2O,	   0.3	  mL,	   0.3	  mmol)	  
was	  added	  and	  the	  resulting	  solution	  was	  stirred	  at	  –78	  °C	  
for	   30	  min.	  The	   solution	  was	   allowed	   to	  warm	   to	   rt	   and	  
stirred	  at	  rt	  for	  30	  min.	  Then,	  bromobenzene	  (70	  μL,	  0.65	  
mmol)	  was	  added,	  followed	  by	  the	  addition	  of	  of	  Pd(dba)2	  
(14	   mg,	   0.025	   mmol)	   and	   RuPhos	   (12	   mg,	   0.025	   mmol).	  
The	   mixture	   was	   stirred	   at	   rt	   for	   16	   h.	   Then,	   35%	  
NH4OH(aq)	  (0.2	  mL)	  was	  added	  and	  the	  solution	  stirred	  at	  
rt	   for	   30	   min.	   The	   solids	   were	   removed	   by	   filtration	  
through	   Celite®	   and	   washed	   with	   Et2O	   (20	  mL).	   The	   fil-­‐
trate	  was	  washed	  with	  H2O	   (20	  mL),	   dried	   (MgSO4),	   fil-­‐
tered	  and	  evaporated	  under	  reduced	  pressure	  to	  give	  the	  
crude	   product.	   Purification	   by	   flash	   column	   chromatog-­‐
raphy	  (SiO2,	  85:15	  petrol-­‐Et2O	  then	  4:1	  petrol:EtOAc)	  gave	  
substituted	  piperazine	  21	  (29	  mg,	  15%)	  as	  a	  colourless	  oil,	  
RF	  (4:1	  petrol-­‐Et2O)	  0.3;	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.36-­‐
7.17	  (m,	  10H),	  5.17	  (br	  s,	  1H),	  3.90	  (d,	  J	  =	  13.0	  Hz,	  1H),	  3.26	  
 
(d,	  J	  =	  12.0	  Hz,	  1H),	  3.07	  (td,	  J	  =	  12.5,	  3.5	  Hz,	  1H),	  2.71	  (d,	  J	  =	  
8.5	  Hz,	  1H),	  2.63	  (dd,	  J	  =	  12.0,	  4.0	  Hz,	  1H),	  2.29	  (td,	  J	  =	  12.0,	  
3.5	  Hz,	  1H),	  1.43	  (s,	  9H),	  1.35	  (s,	  3H),	  1.33	  (s,	  3H);	   13C	  NMR	  
(100.6	  MHz,	  CDCl3)	  δ	  155.2,	  148.4,	  140.9,	  128.0,	  127.9,	  127.2,	  
126.4,	  126.2,	  79.7,	  59.8,	  54.2,	  49.2,	  46.4,	  41.0,	  28.4,	  24.0,	  23.3	  
(one	  Ph	  not	   resolved);	   IR	   (ATR)	  2974,	   1689	   (C=O),	   1494,	  
1448,	  1412,	  1390,	  1364,	  1295,	  10251,	  1230,	  1164,	  1113,	  1029,	  1012,	  
975,	   956,	   762,	   697	   cm-­‐1;	   HRMS	   (ESI)	   m/z	   calcd	   for	  
C24H33N2O2	   (M+H)
+	   381.2537,	   found	   381.2533	   (+0.8	   ppm	  
error),	  and	  vinyl	  carbamate	  22	  (46	  mg,	  30%)	  as	  a	  pale	  yel-­‐
low	  oil,	  RF	  (4:1	  petrol-­‐Et2O)	  0.1;	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  
δ	  7.42	  (d,	  J	  =	  7.5	  Hz,	  2H),	  7.34-­‐7.28	  (m,	  2H),	  7.23-­‐7.17	  (m,	  
1H),	   7.14-­‐6.80	   (br	  m,	   1H),	   4.16	   (br	   s,	   2H),	   3.53	   (br	   s,	   2H),	  
2.51	   (t,	   J	  =	  7.0	  Hz,	  2H),	   1.47-­‐1.42	   (br	  m,	   15H)	   (NH	  not	   re-­‐
solved);	   13C	  NMR	  (100.6	  MHz,	  CDCl3)	  δ	   153.1,	   147.8,	   133.0,	  
128.3,	  126.3,	  125.8,	  90.8,	  81.2,	  55.9,	  43.6,	  40.5,	  29.7,	  28.3;	  MS	  
(ESI)	  m/z	  305	  (M	  +	  H)+;	  IR	  (ATR)	  2974,	  2930,	  1703	  (C=O),	  
1625	  (CH=CH2),	  1454,	  1421,	  1358,	  1327,	  1249,	  1215,	  1155,	  1129,	  
1029,	   835,	   763,	   699	   cm-­‐1;	   HRMS	   (ESI)	   m/z	   calcd	   for	  
C18H28N2O2	   (M	  +	  H)
+	   305.2224,	   found	  305.2213	   (+3.9	  ppm	  
error)	  and	  N-­‐Boc	  piperazine	  16	  (80	  mg,	  53%).	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